TWI233804B - Herbal pharmaceutical compositions for treating immunological disorders - Google Patents
Herbal pharmaceutical compositions for treating immunological disorders Download PDFInfo
- Publication number
- TWI233804B TWI233804B TW91120752A TW91120752A TWI233804B TW I233804 B TWI233804 B TW I233804B TW 91120752 A TW91120752 A TW 91120752A TW 91120752 A TW91120752 A TW 91120752A TW I233804 B TWI233804 B TW I233804B
- Authority
- TW
- Taiwan
- Prior art keywords
- pneumonia
- concentrate
- licorice
- pinellia
- weight
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 49
- 229910001868 water Inorganic materials 0.000 claims abstract description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229930195210 Ophiopogon Natural products 0.000 claims abstract description 18
- 208000006673 asthma Diseases 0.000 claims abstract description 16
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 6
- 241001448424 Ophiopogon Species 0.000 claims abstract 6
- 240000005373 Panax quinquefolius Species 0.000 claims description 71
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 71
- 206010035664 Pneumonia Diseases 0.000 claims description 65
- 239000012141 concentrate Substances 0.000 claims description 64
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 57
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 57
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 51
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 51
- 229940010454 licorice Drugs 0.000 claims description 51
- 241001522129 Pinellia Species 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- 239000008187 granular material Substances 0.000 claims description 34
- 238000011049 filling Methods 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 32
- 235000005340 Asparagus officinalis Nutrition 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 244000003416 Asparagus officinalis Species 0.000 claims description 25
- 241001522232 Pinellia ternata Species 0.000 claims description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 23
- 235000008434 ginseng Nutrition 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 21
- 230000002079 cooperative effect Effects 0.000 claims description 16
- 244000025254 Cannabis sativa Species 0.000 claims description 14
- 241000202807 Glycyrrhiza Species 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 201000009961 allergic asthma Diseases 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 3
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000020932 food allergy Nutrition 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 2
- 229960004717 insulin aspart Drugs 0.000 claims 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 239000012675 alcoholic extract Substances 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- 235000008504 concentrate Nutrition 0.000 description 39
- 238000004809 thin layer chromatography Methods 0.000 description 30
- 229940079593 drug Drugs 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 241000411851 herbal medicine Species 0.000 description 22
- 102000004388 Interleukin-4 Human genes 0.000 description 20
- 108090000978 Interleukin-4 Proteins 0.000 description 20
- 229940028885 interleukin-4 Drugs 0.000 description 20
- 239000000843 powder Substances 0.000 description 20
- 235000008216 herbs Nutrition 0.000 description 17
- 102100037850 Interferon gamma Human genes 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 244000248557 Ophiopogon japonicus Species 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 239000000428 dust Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000006286 aqueous extract Substances 0.000 description 8
- 229930024421 Adenine Natural products 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 238000003306 harvesting Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000004199 lung function Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000234427 Asparagus Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940089161 ginsenoside Drugs 0.000 description 5
- 229930182494 ginsenoside Natural products 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 description 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 5
- 235000019410 glycyrrhizin Nutrition 0.000 description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007721 medicinal effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- -1 cyclic monophosphate Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940029575 guanosine Drugs 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000202726 Bupleurum Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 240000008866 Ziziphus nummularia Species 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 229960003556 aminophylline Drugs 0.000 description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960004958 ketotifen Drugs 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- 235000012141 vanillin Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000218671 Ephedra Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 235000013717 Houttuynia Nutrition 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 241000218378 Magnolia Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000028004 allergic respiratory disease Diseases 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- IGMNYECMUMZDDF-UHFFFAOYSA-N homogentisic acid Chemical compound OC(=O)CC1=CC(O)=CC=C1O IGMNYECMUMZDDF-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- NDNUANOUGZGEPO-QMMMGPOBSA-N (+)-coniine Chemical compound CCC[C@H]1CCCCN1 NDNUANOUGZGEPO-QMMMGPOBSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000206501 Actaea <angiosperm> Species 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101100276463 Caenorhabditis elegans gex-2 gene Proteins 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000134400 Cotinus coggygria Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010061573 Dermatophagoides pteronyssinus antigen p 5 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 101100395869 Escherichia coli sta3 gene Proteins 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000035756 Infantile asthma Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101000608752 Phytolacca americana Lectin-C Proteins 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000008121 Tridax procumbens Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000035559 beat frequency Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940077451 coniine Drugs 0.000 description 1
- 229930016881 coniine Natural products 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000588 effect on asthma Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229940080034 phenobarbital 100 mg Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NDNUANOUGZGEPO-UHFFFAOYSA-N rac-coniine Natural products CCCC1CCCCN1 NDNUANOUGZGEPO-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
1233804 經濟部智慧財產局員工消費合作社印製 A7 ___ B7五、發明説明() 相關申請案 本案爲美國申請案號09/73 5,5 36(於2000年12月14日 申請,並於2002年5月7日獲准公告爲US 63 83 525B1)的部 分連續申請案,茲對照倂入於此。又該美國申請案號 09/735,53 6亦已於中華民國申請,案號爲90 1 28 893,於 2001年11月20日申請。 發明之領域 本發明係關於新穎之草藥組成物及其應用於治療免疫 失調症,尤其是I g E所仲介之疾病,包括,但不限於, 過敏性鼻炎、過敏性結膜炎、過敏性氣喘、異位性溼疹、 異位性皮膚炎、食物過敏、I g E過高症候群及類風濕關 節炎等。本新穎性草藥組成物含麥門冬、半夏、甘草、肺 炎草及花旗參的含水浸膏。本發明也涉及草藥組成物的製 造方法及這些醫藥組成物的療法等。 發明背景 抗原引起的(尤其是過敏原引起)免疫失調症,如氣喘等 ,是世界上已知的嚴重的健康疾患之一。過敏以各式各樣 型態侵襲了世界上2 0 %以上的人群。近幾年來統計顯示 ,與過敏有關的免疫失調其發作的年齡層已逐漸降低,有 更多的小孩及青少年已有了過敏所引起的免疫失調症候群 。譬如,在台灣小孩氣喘症的流行,自1974年的1 . 3 % 增加到1 985年的5 . 0 7 %及1991年的5 . 8 %。又過敏 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -4 - 1233804 經濟部智慧財產局員工消費合作社印製 A7 ___ _B7五、發明説明(j 性鼻炎自1 9 8 5年的7 . 8 4 %增加到1 9 9 1年的 2 0 · 6 %。此外,異位性溼疹從1 9 7 4年的1 . 4 3 %, 1985年的1·23%到1991年的3.84% 。一般認爲早發性的過敏免疫失調可能是環境污染所致。 呼吸道過敏症是一種免疫球蛋白E ( I g E )所引發 的一種反應〔參考 Brinker登於息一然療術刊…(J. Naturopathic Medieine; ( 1 9 9 3 ) 4 : 6 4 — 6 8 )〕 呼吸道過敏所造成的過敏反應有二種:最直接的過敏反應 包括:過敏性鼻炎(稻草熱)及過敏性(外因性)支氣管 氣喘。過敏性鼻炎是由抗原/ I g E結合於過敏化的肥大 細胞及嗜鹼細胞上,造成環單磷酸核酸替(c A Μ P )減 少,而釋出嗜伊紅細胞趨化因子(ECF)及組織胺所引起的。 組織胺結合在H i受體上,會增進血管擴張,增加微血管通 透性,及引發平滑肌收縮,造成鼻塞流鼻水,打噴嚏,及 眼睛癢的症狀。 過敏性氣喘是另一種由I g E所誘發的免疫反應,由 肥大細胞釋出組織胺、緩激肽(bradykinin)、花生四烯酸 (Arachidonic acid)的代謝物,包括白三烯素混合物(即過敏 性慢反應物),以及前列凝素(Thromboxanes) /前列腺素 (Prostagandins)等血管收縮物所造成。由一些白血球釋出的 血小板激活因子(Platelet activating factor)則是另一個誘發 氣喘的因子。依這一種情況,組織胺在c A Μ P減少後釋 出,再作用於H i受體上,造成支氣管攣縮。擬副交感神經 反射作用,及半數的前列腺素是過敏性反應造成支氣管收 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公麓) (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1233804 A7 ______ B7五、發明説明(j 縮之原因。 現今病患的百分比及疾病的嚴重程度一直在上昇,而 當今的治療過敏的方法主要卻仍依靠經驗及嚐試,並非靠 科學的方法。目前,多數患者治療的藥物是針對控制細胞 釋出的介質所產生的症狀。雖然有些藥物,短時間內看來 有效’且副作用少,但長期的效果及副作用仍不知道。例 如,長期服用口服製劑,像類固醇治療(用於治療氣喘症), 現在已知的副作用,如生長延遲,骨質疏鬆,及抑制腎上 腺皮質。 中草藥及醫藥組合物在改進免疫系統的功能及治療慢 性免疫失調方面已爲人知。例如:濱崎(Hamasaki et al.)等人 刊登於人種藥理學期刊(J. Ethnopharmacology ) ( 1 9 9 7 ) 5 0 : 1 2 3 - 1 3 1的文章,顯示中草藥辛脾湯(神秘 湯),能抑止大鼠嗜鹼性白血病一 2 Η 3細胞中由I g E 誘發的白三烯素合成。神秘湯是一種經由冷凍乾燥的中草 藥,由七種中草藥提煉而成,即麻黃、杏仁、厚朴、陳皮 、甘草、柴胡及蘇葉。神秘湯對小孩氣息喘很有用。 戶田等人(Toda et al·)於人j重藥理學期刊(J. Ethnopharmacology ) (1988 ) 24 : 303 — 309 ,發表柴朴湯,證實它能抑止小鼠腹膜中肥大細胞釋出組 織胺。柴朴湯含十種中草藥,即柴胡、半夏、茯苓、黃芩 、大棗、人參、厚朴、蘇葉及生薑。 李等人(Li et al.)在免一—書中( Immunopharmacology ) ( 1 9 9 9 ) ’ 4 3 : 1 1 — 2 1 指 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 1233804 A7 B7 五、發明説明(j (請先閱讀背面之注意事項再填寫本頁) 出補中益氣湯能恢復壓力引起的免疫抑制症。補中益氣湯 含十味中草藥,即人參、白朮、黃耆、當歸、大棗、陳皮 、柴胡、炙甘草、生薑及升麻。 周等人(Zou et al·)在中西醫學雜誌(1 9 9 6 ): 5 2 9 - 5 3 2中指出溫陽通絡合劑,可治療冷症氣喘。 它能改善肺部通氣功能,調節周邊血液及淋巴的交感yS -受體,及減少血淸中的5 -經色胺(5-hydroxytryptamine)的 濃度。溫陽通絡合劑含十二種中草藥,即紅參、製附片、 淫羊藿、乾薑、製黃耆、當歸、麻黃、遠志、桑白皮、生 石骨、五味子、炙甘草。 另網路(www.herb.com.tw)上揭示麥門冬湯,由六味中草 藥組成:麥門冬、半夏、梗米、大棗、人參、甘草。可用於 治療支氣管炎與支氣管氣喘。 經齊部智慧財產局員工消費合作社印製 中草藥的草藥品質控制很重要,因爲草藥的生長條件 ,收穫季節及炮製法等皆會影響其內容物及有效成分。若 這些重要的條件或因素中的任一項,如產地,收穫季節, 及炮製方法不同時,中草藥的效力就會不同。迄今尙無報 告顯示,有任何科學的方法,可用來監控中草藥的品質。 本發明提供新穎而無毒的中草藥方,主要是從台灣及 中國的草藥所製成。這些中草藥合倂的用途,係文獻報告 上前所未有的。這些藥方對治療免疫失調患者特別有效, 尤其是I g E誘發的疾病。本發明的醫藥組成物,對細胞 介白素4 ( I L 一 4 )的向下調節,及對I g E的抑制, 有特別效果。此外,本發明用薄層層析法(T L C )及高 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1233804 A7 B7 五、發明説明(g 效液相層析法(Η P L C ),并4卡南丨士尸 > J 封方劑中每一味中樂作指紋 圖譜分析,以有效控制其品暂 W. ^^ η土 一 κ人仏 、口口頁,並確保每一味樂所含的草 藥皆一致且可重現的。 (請先閲讀背面之注意事項再填寫本頁) 發明的簡述 本發明提供-種醫藥組成物,對免疫失調症有效,包 括’但不限於’過敏性鼻炎、過敏性結膜炎、過敏性氣喘 異位性溼疹、異位性皮膚炎、食物過敏、〗g Ε過高症 候群及類風濕關節炎等。 本案之醫藥組成物含麥門冬、半夏、甘草、花旗參及 肺炎草的含水浸膏。麥門冬、半夏、甘草及花旗參最好用 水萃取,肺炎草最好用酒精萃取,用5〇%酒精更好。其重 量比例最好是麥門冬”半夏:甘草:花旗參:肺炎草=3 :2 : 1 : 1 : 1。 經濟部智慧財產局員工消費合作社印製 麥門冬、半夏、甘草、花旗參及肺炎草的各個含水浸 膏,最好各別過濾及濃縮。麥門冬的濃縮物中的固形物含 重占約麥門冬生藥的20-30%重量比,最好爲約25%。濃縮 物中的固形物含量,就是除去水分的濃縮物。以麥門冬爲 例,其濃縮物含相當量的水分(即麥門冬濃縮物中,約 5 8 %爲水分),其餘草藥的濃縮物的確固形物含量,約與濃 縮物相同(即水分不多)。半夏濃縮物占約半夏生藥的約 15-25%,最好爲約20%的重量比。甘草濃縮物占約甘草生 樂的15-25%,最好爲約20%的重量比。花旗參濃縮物占約 花旗篸生樂的約19-29%,最好爲約24.3%的重量比。肺炎 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -8- 1233804 A7 __ ___B7 五、發明説明(g 草濃縮物占約肺炎草生藥的5_10%,最好爲約7·8%的重量 比。 (請先閲讀背面之注意事項再填寫本頁) 除麥門冬不作成顆粒外,半夏、甘草 '花旗參及肺炎 早的濃縮物,分別各個作成顆粒。甘草顆粒占甘草生藥約 1 6-26%,最好約21 %的重量比。花旗參顆粒占花旗參生藥 約27-37%,最好約32%的重量比。肺炎草顆粒占肺炎草生 藥約37-47%,最好約42%的重量比。 本發明也提供製造此醫藥組成物的方法。該方法須各 別卒取麥門冬、半夏、甘草、花旗參及肺炎草。麥門冬、 半夏、甘草及花旗參是用水煎煮萃取的。肺炎草是用酒精 ’最好是5 0 %酒精,以熱迴流方式萃取。萃取後的浸膏, 各別過濾除去藥渣,各個濾液再以減壓濃縮方式,在溫度 55°C,壓力30托(torr )下濃縮。每一濃縮物再加入一種 賦型劑,最好是玉米澱粉,以成爲糊狀浸膏,再用噴霧乾 燥造粒法,在進料溫約l〇5t及出料溫約76-77°C的條件下 造粒。半夏、甘草、花旗參及肺炎草的顆粒再與麥門冬的 濃縮物混合成顆粒混合物,以備充塡膠囊中。 經濟部智慧財產局W工消費合作社印製 又,萃取物(體積)對生藥(重量)的比約20:1。水 萃取時間最好約30分鐘。酒精萃取時間最好約30分鐘。 本發明的醫藥組成物雖與母案申請的醫藥組成物含相 同的五種草藥混合物,但本發明不同的是,它含這些草藥 的含水浸膏;而母案申請的醫藥組成物含的主要是這些草 藥的粉末(雖然麥門冬也是用含水浸膏)。在作用及藥效 上,本案組成物優於母案組成物,可能是萃取過程中,有 本紙張尺度適用中國國家標隼(CNS )八4規格(210X297公釐) -9- 1233804 Α7 Β7 經濟部智慧財產局員工消費合作社印製 五、發明説明(9 效成分釋出的緣故。 圖式簡單說明 圖1是麥門冬的Η P L C圖譜。整個圖譜的圖形是使 用Η P L C.分析法1 (如下述),以2 1 4 n m波長測得 的。圖中有二個波峰,6115 — 1及6115 — 2 ,其 滯留時間分別爲1 1 · 5分及1 3分。此二波峰可用來鑑 定麥門冬。 圖2是半夏的Η P L C圖譜。有二個化學指標成分, 即腺嘌哈(adenine)及鳥糞嘌玲(guanosine),用Η P L C分 析法2,以2 6 0 n m波長測定。腺嘌呤的滯留時間是 1 4 . 8分,鳥糞嘌呤的滯留時間是1 7分。 圖3是甘草的HP L C圖譜。有一個化學指標成分, 甘草酸(glycyrrhizin )是用HPLC分析法1 ,以250 n m波長測定的,其滯留時間爲4 6 _ 4分。 圖4是花旗參的HP L C圖譜。有一個化學指標成分 ,人參官苷 R b 1 ( ginsenoside Rbi),是用 HPLC 分析 法3,以2 0 3 n m波長測定。其滯留時間爲3 7 . 5分 〇 圖5是肺炎草的Η P L C圖譜。有4個獨特波峰’ F Υ — 1到F Υ — 4 ,係用Η P L C分析法2 ’以2 5〇 n m波長測定的。其滯留時間分別爲F Υ 一 1 = 2 8分; FY— 2 = 31 · 6 分;FY— 3 二 33 · 5 分;FY — 4 = 1 8 . 3 分。 本紙張尺度適用中國國家標率(CNS ) Α4規格(210X297公釐) _ 1〇 - (請先閱讀背面之注意事項再填寫本頁)1233804 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 ___ B7 V. Description of Invention () Related Application This application is US Application No. 09/73 5,5 36 (applied on December 14, 2000, and in 2002 On May 7, part of the serial applications that were approved to be published as US 63 83 525B1) are hereby incorporated herein. The US application number 09 / 735,53 6 has also been filed in the Republic of China, with the case number 90 1 28 893, which was filed on November 20, 2001. FIELD OF THE INVENTION The present invention relates to novel herbal compositions and their applications in the treatment of immune disorders, especially diseases mediated by IgE, including, but not limited to, allergic rhinitis, allergic conjunctivitis, allergic asthma, allergies Atopic eczema, atopic dermatitis, food allergies, Ig E syndrome, and rheumatoid arthritis. The novel herbal composition contains aqueous extracts of Ophiopogon, Pinellia ternata, licorice, pneumonia, and American ginseng. The present invention also relates to a method for producing herbal compositions and therapies for these pharmaceutical compositions. BACKGROUND OF THE INVENTION Antigen-induced (especially allergen-induced) immune disorders, such as asthma, are one of the serious health conditions known in the world. Allergies affect more than 20% of the world's population in various forms. Statistics in recent years show that the age of onset of allergy-related immune disorders has gradually decreased, and more children and adolescents have already developed immune disorders caused by allergies. For example, the prevalence of infantile asthma in Taiwan increased from 1.3% in 1974 to 5.07% in 1985 and 5.8% in 1991. Allergic (please read the precautions on the back before filling this page) This paper size applies the Chinese National Standard (CNS) A4 specification (210X 297 mm) -4-1233804 Printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 ___ _B7 V. Description of the invention (J rhinitis has increased from 7.84% in 1985 to 20.6% in 1991. In addition, atopic eczema has increased from 1.74 in 1974. 43%, from 1.23% in 1985 to 3.84% in 1991. It is generally believed that early-onset allergic immune disorders may be caused by environmental pollution. Respiratory allergies are caused by an immunoglobulin E (IgE) A kind of reaction [Refer to Brinker published in the journal Yi Yiran Therapeutic Journal ... (J. Naturopathic Medieine; (1 9 9 3) 4: 6 4 — 6 8)] There are two types of allergic reactions caused by respiratory allergies: the most direct Allergic reactions include: allergic rhinitis (straw fever) and allergic (exogenous) bronchial asthma. Allergic rhinitis is caused by the combination of antigen / Ig E on allergic mast cells and basophils, causing cyclic monophosphate replacement (C A Μ P) decreases, and releases eosinophil chemokine (ECF) and Caused by weaver. Histamine binds to the Hi receptor, which can increase vasodilation, increase microvascular permeability, and cause smooth muscle contraction, causing nasal congestion, runny nose, sneezing, and itchy eyes. Allergic asthma is Another immune response induced by I g E, metabolites of histamine, bradykinin, arachidonic acid, including leukotrienes (ie, slow allergic reactions) released by mast cells Reactants) and vasoconstrictors such as Thromboxanes / Prostagandins. Platelet activating factor released by some white blood cells is another factor that induces asthma. According to this one In some cases, histamine is released after c A MP decreases, and then acts on Hi receptors, causing bronchoconstriction. Parasympathetic reflex effect, and half of the prostaglandins are caused by allergic reactions in bronchus. National Standard (CNS) A4 specification (210X297 feet) (Please read the notes on the back before filling this page) Intellectual Property Bureau of the Ministry of Economic Affairs Printed by the Industrial and Consumer Cooperatives 1238804 A7 ______ B7 V. Explanation of the invention (j Reason for contraction. The percentage of patients and the severity of the disease have been rising, but the current methods of treating allergies still rely on experience and attempts, not relying on scientific methods. Currently, most patients are treated with drugs aimed at controlling the symptoms of the release of the cells from the cells. Although some drugs appear effective in a short time and have few side effects, the long-term effects and side effects are still unknown. For example, long-term oral preparations, such as steroid therapy (used to treat asthma), are now known to have side effects such as delayed growth, osteoporosis, and inhibition of the adrenal cortex. Chinese herbal medicines and medicinal compositions have been known for improving the function of the immune system and treating chronic immune disorders. For example: Hamasaki et al. And other articles published in J. Ethnopharmacology (199.7) 5 0: 1 2 3-1 31 1 show Chinese herbal medicine Xinpi soup (mysterious soup) ), Can inhibit Ig E-induced leukotriene synthesis in rat basophilic leukemia cells. Mystery Soup is a freeze-dried Chinese herbal medicine made from seven Chinese herbal medicines, namely ephedra, almond, magnolia, tangerine peel, licorice, bupleurum, and perilla leaf. Mystery soup is useful for children to breathe. Toda et al. (Toda et al.) In J. Ethnopharmacology (1988) 24: 303-309, published Chai Pu Tang, confirmed that it can inhibit the release of histamine from mast cells in the peritoneum of mice . Chai Pu Tang contains ten kinds of Chinese herbal medicines, namely Bupleurum, Pinellia, Poria, Cotinus coggygria, jujube, ginseng, Magnolia, Su Ye and ginger. Li et al. In Immunopharmacology (1 9 9) '4 3: 1 1 — 2 1 refers to the paper size applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) ) (Please read the precautions on the back before filling this page) 1233804 A7 B7 V. Description of the invention (j (Please read the precautions on the back before filling out this page) Debuzhong Yiqi Decoction can restore stress-induced immunosuppression .Buzhong Yiqi Decoction contains ten flavors of Chinese herbal medicines, namely ginseng, atractylodes, astragalus, angelica, jujube, Chenpi, Bupleurum, Zhigancao, ginger and Cimicifuga. Zhou et al. (Zou et al.) In Chinese and Western Medicine Journal (19 9 6): 5 2 9-5 3 2 pointed out that Wenyangtong complexing agent can treat cold asthma. It can improve lung ventilation function, regulate peripheral blood and lymphatic sympathetic yS-receptors, and Decrease the concentration of 5-hydroxytryptamine in blood tincture. Wenyangtong complexing agent contains twelve Chinese herbal medicines, namely red ginseng, edible tablets, epimedium, dried ginger, scutellaria baicalensis, angelica, Ephedra, Polygala, Morus alba, Raw Stone Bone, Schisandra, and Licorice. Also on the Internet (www.herb.com.tw) Shemai asparagus soup is composed of six Chinese herbal medicines: asparagus, pinellia, stem rice, jujube, ginseng, licorice. It can be used to treat bronchitis and bronchial asthma. It is printed by the Consumers' Cooperative of the Intellectual Property Bureau of the Ministry of Qi and printed on Chinese herbs. The quality control of herbal medicine is very important, because the growth conditions, harvest season and processing methods of herbal medicine will affect its contents and effective ingredients. If any of these important conditions or factors, such as origin, harvest season, and processing methods The effectiveness of Chinese herbal medicines will be different at different times. So far, there are no reports showing that there are any scientific methods to monitor the quality of Chinese herbal medicines. The present invention provides novel and non-toxic Chinese herbal medicines, which are mainly made from herbs in Taiwan and China The use of these Chinese herbal medicines is unprecedented in literature reports. These prescriptions are particularly effective in treating patients with immune disorders, especially Ig E-induced diseases. The pharmaceutical composition of the present invention is effective for interleukin 4 (IL-1 4) Down regulation and inhibition of I g E have special effects. In addition, the present invention uses thin layer chromatography (T LC) and high paper size are applicable to Chinese National Standard (CNS) A4 specification (210X297 mm) 1233804 A7 B7 V. Description of the invention (g high performance liquid chromatography (ΗPLC), and 4 Kanan 丨 Shishen > Analysis of fingerprints of each flavor of Jelle in Zhongfeng Formula to effectively control its quality. ^^ η 土 一 κ 人 仏, 口 口 口 口, and ensure that the herbs contained in each flavor of Yue are consistent and reproducible. (Please read the notes on the back before filling this page) Brief description of the invention The present invention provides a pharmaceutical composition that is effective for immune disorders, including 'but not limited to' allergic rhinitis, allergic conjunctivitis, allergic asthma Atopic eczema, atopic dermatitis, food allergies, g e syndrome and rheumatoid arthritis. The pharmaceutical composition in this case contains aqueous extracts of Ophiopogon, Pinellia ternata, Licorice, American Ginseng and Pneumonia. Ophiopogon, pinellia, licorice and ginseng are best extracted with water, pneumonia is best extracted with alcohol, and 50% alcohol is better. The best weight ratio is Ophiopogon sylvestris: Pinellia: Glycyrrhiza: American Ginseng: Pneumonia = 3: 2: 1: 1: 1. The employee cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs prints Ophiopogon, Pinellia ternata, Licorice, Each aqueous extract of American ginseng and pneumonia is best filtered and concentrated separately. The solid content of the concentrate of O. asparagus accounts for about 20-30% by weight of O. asparagus crude, preferably about 25 %. The solid content in the concentrate is the concentrate from which moisture is removed. Taking asparagus as an example, its concentrate contains a considerable amount of water (that is, about 58% of the asparagus concentrate is water), and the rest The concentration of herbal concentrates is about the same as that of the concentrate (that is, there is not much water). Pinellia concentrate accounts for about 15-25% of Pinellia crude drug, preferably about 20% by weight. Licorice concentrate accounts for About 15-25% of licorice shengle, preferably about 20% by weight. American ginseng concentrate is about 19-29% of ginseng shengsheng, preferably about 24.3% by weight. Pneumonia paper Standards are applicable to China National Standard (CNS) A4 specifications (210X297 mm) -8- 1233804 A7 __ ___B7 V. Description of the invention (g The grass concentrate accounts for about 5-10% of the pneumoniae crude drug, preferably about 7.8% by weight. (Please read the precautions on the back before filling this page.) Except for asparagus, the pinellia and licorice 'Ginseng and early pneumonia concentrates are made into granules respectively. Glycyrrhiza granules account for about 16-26% of the licorice crude drug, preferably about 21% by weight. Ginseng particles account for about 27-37% of the ginseng crude drug. It is about 32% by weight. The pneumonia granules account for about 37-47%, preferably about 42% by weight of the pneumonia herbal medicine. The present invention also provides a method for manufacturing the pharmaceutical composition. Asparagus, Pinellia ternata, licorice, American ginseng, and pneumonia. O. asparagus, Pinellia ternata, licorice, and American ginseng are decoction extracted with water. Pneumonia spp. Is made with alcohol, preferably 50% alcohol, with hot reflux. Extraction. The extracted extracts are separately filtered to remove the drug residue, and each filtrate is concentrated under reduced pressure at a temperature of 55 ° C and a pressure of 30 Torr. Each concentrate is added with an excipient. It is best to use corn starch to make a paste-like extract. Granulated at a temperature of about 105t and a discharge temperature of about 76-77 ° C. The granules of Pinellia ternata, licorice, American ginseng, and pneumonia are mixed with the concentrate of Ophiopogon to form a granular mixture for filling In the capsule. Printed by the W Industrial Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. The ratio of the extract (volume) to the crude drug (weight) is about 20: 1. The water extraction time is preferably about 30 minutes. The alcohol extraction time is about 30. Although the pharmaceutical composition of the present invention contains the same five kinds of herbal medicine mixture as the pharmaceutical composition of the parent application, the difference of the present invention is that it contains an aqueous extract of these herbs; while the pharmaceutical composition of the parent application contains The main thing is the powder of these herbs (though Macedonian also uses aqueous extracts). In terms of action and efficacy, the composition in this case is superior to the composition in the mother case. It may be that during the extraction process, the paper size is applicable to China National Standard (CNS) 8 4 (210X297 mm) -9-1233804 Α7 Β7 Economy Printed by the Ministry of Intellectual Property Bureau's Consumer Cooperatives 5. The invention description (9 reasons for the release of the effective ingredients. The diagram is a simple illustration. Figure 1 is a map of Mai Mendong's PLC PLC. The graphics of the entire map are using the PL C. Analysis Method 1 (As described below), measured at a wavelength of 2 1 4 nm. There are two peaks in the figure, 6115-1 and 6115-2, with retention times of 1 1 · 5 minutes and 13 minutes respectively. These two peaks can be used to Identification of Ophiophyllum. Figure 2 is the PLC spectrum of P. ternata. It has two chemical index components, namely adenine and guanosine. The P. PLC analysis method 2 was used to measure 2 6 0 nm. Wavelength measurement. The retention time of adenine is 14.8 minutes, and the retention time of guanosine is 17 minutes. Figure 3 is the HP LC spectrum of glycyrrhiza. There is a chemical index component, glycyrrhizin is analyzed by HPLC Method 1, measured at 250 nm, with a retention time of 4 6 _ 4 points. Figure 4 is the HP LC spectrum of American ginseng. There is a chemical index component, ginsenoside Rbi (ginsenoside Rbi), which is determined by HPLC analysis method 3 at a wavelength of 230 nm. Its retention time is 37. 5 minutes Figure 5 is the Η PLC spectrum of P. pneumoniae. There are 4 unique peaks 'F Υ — 1 to F Υ — 4 measured by the Η PLC analysis method 2' at a wavelength of 2 50 nm. The residence time is F Υ 1 = 2 8 points; FY— 2 = 31 · 6 points; FY — 3 2 · 33 · 5 points; FY — 4 = 1 8. 3 points. This paper scale applies Chinese national standard rate ( CNS) Α4 specifications (210X297 mm) _ 1〇- (Please read the precautions on the back before filling this page)
、1T -線_· 1233804 A7 經濟部智慧財產局員工消費合作社印製 B7五、發明説明(d 圖6是比較花旗參的(1 )粉末,(2 ) 95%酒精浸膏, (3)水浸膏,(4) 50%酒精浸膏對IgG2a及IgE値的影響 。其値以平均値±S EM表示之。本圖顯示花旗參的50%酒精 浸膏,在減低IgE及增加IgG方面,比水浸膏佳。 圖7是比較肺炎草的(1 )粉末,(2 ) 9 5 %酒精浸膏, (3 )水浸膏,(4 ) 50%酒精浸膏對IgE,IgG2a,IL-4及 IFN-γ値的影響。其値以平均値土SEIvi表示之。*表示與控 制組比較的有意義差。結果顯示肺炎草的50%酒精浸膏, 在抑制IgE及增加IgG方面,效果最佳。 圖8比較STA-36,STA-4及控制組(安慰劑組)對 BALB/c小鼠血淸中IgG及IgE値的影響。S丁A_30是母案中 所揭示的醫藥組成物,STA-4是本發明的醫藥組成物。*表 示STA-4與控制組間的有顯著差異(p < 0.05)。數値以平 均値iS EM表示之。STA-36的劑量(20 mg/20 g鼠重)是 STA-4 劑量(10 mg/20 g 鼠重)的二倍(即 STA6 : STA-4 = 2:1)。結果顯示,雖然STA-36及STA-4皆對IgE有抑制 ,但只有STA-4與控制組間具有顯著差異。至於IgG,STA-36 及 STA4 皆增加 IgG 。 雖然 STA-36 對 IgG 値 的增加 ,較 STA-4的高,但兩者的增加,與控制組的比較,並不具有 顯著差異。 圖9是STA-3 6及STA-4對肺功能影響的比較硏究。 數値以平均値土S EM表示之。對照於控制組(p < 0.05 ), STA-36及STA-4皆顯示對肺功能有改善(依乙醯膽鹼的測 定決定)。依STA-36及STA-4兩者的治療來看,雖然 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) -11 - Μ 1233804 Β7 ____ 五、發明説明(j STA-4效果較ST A-36佳,·但由於每組受試動物數目的不足 ,STA-36及STA-4兩組間的差異,並不具統計學上的有意 義差。STA-36的劑量(20 mg/20 g小鼠重)爲STA-4(10 mg/20 g小鼠重)的二倍。 圖10是比較STA-4與一般治療藥物包括Ketotifen, Predisolone 及 Aminophylline 等對 IgE,IgG ’ IL-4 及 IFN-γ 的效果。數値以平均値±SEM^示之。*表示對照於控制組 有顯著差異。本硏究顯示,STA-4顯著地降低IgE値,但顯 著地增高IgG2a,1IL-4及 IFN-γ値。 發明詳述 在母案(序號爲〇9/73 5,536的美國專利申請案,中華民 國第90 1 28 893號專利申請案)中,提供6個醫藥組成物(所 謂 STA— 3 系列的 STA— 3 1 〜STA - 36)。 STA - 3 1〜STA—3 6草藥組成物內容如表1所示 (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 表1,S T A — 3系列草藥組成物 草藥組成物 草藥1 草藥2 草藥3 草藥4 草藥5 . STA-31 麥門冬 半夏 甘草 黨參 台灣麻芝糊 STA-32 麥門冬 半夏 甘草 黨參 魚腥草 STA-33 麥門冬 半夏 甘草 黨參 肺炎草 STA-34 麥門冬 半夏 甘草 花旗參 台灣麻,米胡 STA-35 麥門冬 半夏 甘草 花旗參 ^ /<r , /| 口/] 魚腥草 STA-36 麥門冬 半夏 甘草 花旗參 肺炎草 本紙張尺度適用中國國家標準(CNS ) M規格(2ΐ〇χ297公釐) 1233804 A7 _ B7 五、發明説明(、 此S T A - 3系列的6個組成物中,以S T A - 3 6 爲最佳。 (請先閲讀背面之注意事項再填寫本頁)、 1T -line _ · 1233804 A7 Printed by B7 of Consumer Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs V. Invention description (d Figure 6 is a comparison of American Ginseng (1) powder, (2) 95% alcohol extract, (3) water Extracts, (4) The effect of 50% alcohol extracts on IgG2a and IgE 値. The mean is expressed as mean ± S EM. This figure shows the 50% alcohol extract of American ginseng in reducing IgE and increasing IgG. Better than water extract. Figure 7 compares (1) powder, (2) 95% alcohol extract, (3) water extract, (4) 50% alcohol extract against IgE, IgG2a, IL- 4 and the effect of IFN-γ. It is expressed as the average soil SEIvi. * Indicates a significant difference compared with the control group. The results show that the 50% alcohol extract of pneumonia grass is the most effective in inhibiting IgE and increasing IgG. Figure 8 compares the effects of STA-36, STA-4 and the control group (placebo group) on the IgG and IgE 値 in the blood 淸 of BALB / c mice. Sine A_30 is a pharmaceutical composition disclosed in the mother case. STA-4 is a pharmaceutical composition of the present invention. * Indicates a significant difference between STA-4 and the control group (p < 0.05). Numbers are expressed as the mean 値 iS EM. The dose of STA-36 20 mg / 20 g rat weight) is twice the dose of STA-4 (10 mg / 20 g rat weight) (ie STA6: STA-4 = 2: 1). The results show that although both STA-36 and STA-4 are IgE is inhibited, but only STA-4 and the control group have significant differences. As for IgG, STA-36 and STA4 all increase IgG. Although STA-36 increases the IgG tritium more than STA-4, but both Compared with the control group, the increase was not significantly different. Figure 9 is a comparative study of the effects of STA-3 6 and STA-4 on lung function. Numbers are expressed as the average soil S EM. Compared with the control group (P < 0.05), both STA-36 and STA-4 showed improvement in lung function (determined by the determination of acetylcholine). According to the treatment of both STA-36 and STA-4, although this paper Standards are applicable to China National Standard (CNS) A4 specifications (210X297 mm) (Please read the precautions on the back before filling out this page) -11-Μ 1233804 Β7 ____ 5. Description of the invention (j STA-4 is more effective than ST A-36 Good, but due to the insufficient number of animals in each group, the difference between STA-36 and STA-4 was not statistically significant. The dose of STA-36 (20 mg / 20 g mouse weight) is twice that of STA-4 (10 mg / 20 g mouse weight). Figure 10 compares STA-4 with general treatment drugs including Ketotifen, Predisolone, and Aminophylline for IgE, IgG 'IL-4 and Effect of IFN-γ. Figures are shown as mean ± SEM. * Indicates significant difference between control and control group. This study showed that STA-4 significantly reduced IgE 値, but significantly increased IgG2a, 1IL-4 and IFN-γ 値. Detailed description of the invention In the parent case (U.S. Patent Application No. 09/73 5,536, Republic of China No. 90 1 28 893 Patent Application), 6 pharmaceutical compositions (so-called STA-3 series of STA-3 are provided 1 to STA-36). STA-3 1 ~ STA-3 6 The contents of the herbal composition are shown in Table 1 (please read the precautions on the back before filling this page) Order printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs, Table 1, STA-3 series of herbs Composition Herb Composition Herb 1 Herb 2 Herb 3 Herb 4 Herb 5. STA-31 Maimendong Pinellia Glycyrrhiza Codonopsis Taiwan Mochi Paste STA-32 Maimendong Pinellia Glycyrrhiza Codonopsis Houttuynia STA-33 Maimendong Ban Licorice Dangshen Pneumonia STA-34 Maimens Pinellia Glycyrrhiza American Ginseng Taiwan Hemp, Mihu STA-35 Maimens Pinellia Glycyrrhiza American Ginseng ^ / < r, / | Mouth /] Houttuynia STA-36 Wheat Asparagus pinellia licorice ginseng pneumonia pneumonia herbal paper scales apply Chinese National Standard (CNS) M specifications (2 × 〇χ297 mm) 1233804 A7 _ B7 V. Description of the invention (、 In the 6 components of this STA-3 series, STA-3 6 is the best. (Please read the notes on the back before filling this page)
本發明係針對改善STA-36的療效,而對STA-36所含 草藥,即麥門冬、半夏、甘草、花旗參及肺炎草,使用種 種萃取法。其結果所產生的醫藥組成物叫STA-4。STA-36 及STA-4皆具有治療免疫失調症的藥效,尤其是在抑制IgE 的產生。 抗原或過敏原誘發的氣喘是一種呼吸系統的疾病,主 要是由於慢性發炎反應。這種發炎反應是因爲發炎因子, 如血小板激活因子,組織胺,前列腺素,白三烯素等自細 胞釋出的緣故。發炎反應刺激T-淋巴(T-細胞),尤其是 CD4 +細胞內的抗原反應。CD4 +細胞有兩型。Thl型的CD4 + 細胞分泌細胞素(IFN-γ) ; Th2型的CD4 +細胞分泌細胞介 白素(IL-4)。多數的過敏性氣喘病患屬於Th2型。過敏原 刺激Th2細胞使產生IL-4,IL-4再轉而誘使B淋巴產生並 分泌IgE 〇 STA-3 6及STA-4的組成藥物內容的比較如表2所示。 表2 STA-36及STA-4的草藥內容 麥 門 冬 半夏 甘草 花旗參 肺炎草 STA-36 水 浸 膏 生藥粉末 生藥粉末 生藥粉末 生藥粉末 STA-4 水 浸 膏 水浸膏 水浸膏 水浸膏 50%酒精浸膏 經濟部智慧財產局員工消費合作社印製 S T A - 3各醫藥組成物中組成藥味的生藥名,植物 學名,科名及主要成分如表3所示。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -13- !233804 五、發明説明( A7 B7 經濟部智慧財產局員工消費合作社印製 袠3 S T A - 3系列醫藥組成物組成藥味之生藥名,植 物學名,及主成分 草藥 生藥名 植物働物學名 科 名 主成分 麥門冬 Tuber Ophiopogonis Japanici Ophiopogon japonicus Ker. Gawl 百 合 科 沿階草皂苷 (ophiopogonin),魯其斤可巷 普元(ruscogenin),β-榖固 醇(β-sitosterol),豆固 醇(stigmasterol) 花旗參 Radix Panacis Quinquefolii Panax quinquefolium L. 五 加 科 ^素,人參奎酮 半夏 Tuber Pinellia Rhizoma Pinellia Tematae Pinellia ternata (Thunb.) Breitenbach 天 南 星 科 歐毒芽鹼(coniine),原白 豆翁素(protoanemonin), 尿黑酸(homogentisic acid),菸鹼,天門冬胺 酸,麩胺酸,精胺酸,β-穀固醇,膽固醇 甘草 Radix Glycyrrhizae Uralensis Glycyirhiza uralensis Fischer 或 Glycyrrhiza glabra Linne 豆 科 氮雜環丁烷-2-羧酸,天門 冬胺酸酯,高絲胺酸,二 胺基丁酸,毛地黃苷類 肺炎草 Herba Tridacis Procumbentis Tridax procumbens Linn. 菊 科 多糖 (請先閱讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -14- 1233804 A7 ____B7The present invention aims to improve the curative effect of STA-36, and uses various extraction methods for the herbs contained in STA-36, namely, asparagus, pinellia ternata, licorice, American ginseng and pneumonia. The resulting pharmaceutical composition is called STA-4. Both STA-36 and STA-4 are effective in treating immune disorders, especially in inhibiting the production of IgE. Antigenic or allergen-induced asthma is a disease of the respiratory system, mainly due to a chronic inflammatory response. This inflammatory response is due to the release of inflammatory factors such as platelet activating factor, histamine, prostaglandin, leukotrienes, etc. from the cells. The inflammatory response stimulates T-lymph (T-cell), especially the antigen response in CD4 + cells. CD4 + cells have two types. CD4 + cells of Thl type secrete cytokines (IFN-γ); CD4 + cells of Th2 type secrete interleukins (IL-4). Most patients with allergic asthma are of type Th2. Allergens stimulate Th2 cells to produce IL-4, and IL-4 in turn induces B lymphocytes to produce and secrete IgE. STA-3 6 and STA-4 are compared as shown in Table 2. Table 2 Herbal contents of STA-36 and STA-4 Maitongdong pinellia licorice Ginseng pneumonia pneumoniae STA-36 Water extract crude drug powder crude drug powder crude drug powder crude drug powder STA-4 water extract water extract water extract water extract 50% Alcohol Extract. The pharmacological names, botanical names, family names, and main ingredients of each of the pharmaceutical ingredients in STA-3 printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs are shown in Table 3. This paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) -13-! 233804 V. Description of the invention (A7 B7 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 袠 3 STA-3 series of pharmaceutical composition composition medicine taste The name of the original medicine, botanical, and the main ingredient of the herb, the name of the medicine, the name of the plant, the name of the family, the name of the main ingredient, Tuer Ophiopogonis Japanici Ophiopogon japonicus Ker. Gawl ruscogenin), β-sitosterol, stigmasterol, Radix Panacis Quinquefolii Panax quinquefolium L. Pentaquinone, Tuber Pinellia Rhizoma Pinellia Tematae Pinellia ternata (Thunb. Breitenbach Coniine, protoanemonin, homogentisic acid, nicotine, aspartic acid, glutamic acid, arginine, β-sitosterol Radix Glycyrrhizae Uralensis Glycyirhiza uralensis Fischer or Glycyrrhiza glabra Linne Alkan-2-carboxylic acid, aspartate, homoserine, diaminobutyric acid, digitin pneumonia Herba Tridacis Procumbentis Tridax procumbens Linn. Compositae polysaccharide (please read the precautions on the back before filling (This page) The size of the paper used for this edition applies to the Chinese National Standard (CNS) A4 (210X297 mm) -14- 1233804 A7 ____B7
五、發明説明(A (請先閲讀背面之注意事項再填寫本頁) 麥門冬屬於百合科,其塊莖具有藥效。最佳採收期爲 夏天,採收後,塊莖洗淨,去雜質及細根,再經日曬保存 備用。麥門冬是根的膨大部分。麥門冬產於中國的浙江, 四川’江穌等售。示等人在中藥材期刊(China Journal ofV. Description of the invention (A (please read the notes on the back before filling out this page) Ophiopogon belongs to the family Liliaceae, and its tubers have medicinal effects. The best harvest time is summer. After harvest, tubers are washed to remove impurities And fine roots, and then stored for future use. Ophiopogon is a swollen portion of the root. Ophiopogon is produced in Zhejiang, China and Sichuan, and sold by Jiang Su and others. Shi et al.
Chinese Materia Medica) 16 : 584 〜585 中報導稱麥 門冬含水萃取物(浸膏)能加強小鼠排除靜脈中焦炭粒子 ,並拮抗環磷醯胺(clophosphamide)引起的白血球缺乏症。 花旗參屬五加科,其藥效部分在根。花旗參產於北美 及加拿大。在法國及中國北方也有栽培。最佳採收季節爲 秋天。 半夏屬於天南星科,其塊莖具有藥效。半夏產於中國 的四川,湖北,河南,貴州及安徽省。正常採收期在7月 到9月之間。在台灣的台中縣也有。 經濟部智慧財產局員工消費合作社印製 甘草屬於豆科。其根及葡萄莖帶或不帶表皮,皆具有 藥效。甘草含2 . 5 %以上的甘草酸(依乾燥藥材計算) ,可做爲甘草的指標成分。甘草生長在中國內蒙,甘肅, 新疆,及東北部。最佳採收季節在春或秋季。在台灣的台 中縣亦有甘草。甘草的根具有消炎作用,可單獨使用,以 助緩解氣喘症狀。參閱H. W. Μ 〇 r n i n g s t a r的書:感性的睦j[戈 二遍人及社群的另類變化(Sentient Times:Alternative f〇r Personal and Community Transformation) ( 1 9 9 8 ) ; 6 :16 - 17。甘草根對支氣管炎也很好用。見T· Da Vlt 的書: 革命性工作( 1 9 9 7 ),ΡΡ·66- 79。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ 297公~ ~ 1233804 A7 _________B7Chinese Materia Medica) 16: 584-585 reported that aqueous extracts of Ophiopogon asparagus can strengthen the elimination of coke particles in veins in mice and antagonize white blood cell deficiency caused by clophosphamide. American ginseng belongs to the family Acanthaceae, and its medicinal effect is in the root. Ginseng is produced in North America and Canada. It is also cultivated in France and northern China. The best harvest season is autumn. Pinellia belongs to Araceae and its tubers have medicinal effects. Pinellia is produced in Sichuan, Hubei, Henan, Guizhou and Anhui provinces in China. The normal harvest period is between July and September. It is also found in Taichung County, Taiwan. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs Licorice belongs to the family Leguminosae. Its roots and grape stems are with or without epidermis, and have medicinal effects. Licorice contains more than 2.5% glycyrrhizic acid (calculated based on dried medicinal materials), which can be used as an index component of licorice. Licorice grows in Inner Mongolia, Gansu, Xinjiang, and the northeast of China. The best harvest season is spring or autumn. Licorice is also found in Taichung County, Taiwan. Licorice roots have anti-inflammatory effects and can be used alone to help relieve asthma symptoms. See H.W.Mr n i n g s t a r 's book: Sensitive Harmony [Sentient Times: Alternative for Personal and Community Transformation (19 9 8); 6: 16-17. Licorice root is also good for bronchitis. See T. Da Vlt's book: Revolutionary Work (199 7), PP · 66-79. This paper size applies to China National Standard (CNS) Α4 size (210 × 297 male ~ ~ 1233804 A7 _________B7
五、發明説明(A 肺炎草屬於菊科。全株乾燥植物具有藥效。肺炎草屬 在台灣的南投縣’台中縣,員林縣及台中市皆可見,在南 (請先閱讀背面之注意事項再填寫本頁) 美也有。V. Description of the invention (A Pneumoniae belongs to the family Asteraceae. The entire plant is dry and has medicinal effects. Pneumonia is found in Nantou County, Taichung County, Yuanlin County and Taichung City in Taiwan. Please read the note on the back Please fill in this page again.) There is beauty too.
Dlwan 等人發表於g 8 3 )’ 2 7 : 3 2 - 3 6,揭示從肺炎草葉子抽出的汁,對 傷口的收口及肉芽生長的效果,類似得沙美松( dexamethasone ),但在張力及上皮形成方面卻與得沙美松 (dexamethasone )有拮抗效果。甘等人在中國醫藥學^^ ( 1 9 7 7 ) ’ 8 · 5 26 ’中揭不肺炎草的葉可用於 消炎,解熱,治療肺炎及咳嗽。 STA-36及STA-4草藥組成物的製備方法如下: A. SJA-36草藥組成物的製備 STA-36草藥組成物的製備方法如下: (1) 半夏、甘草及花旗參的根以及肺炎草的全草細切, 脫水,硏磨並用篩網過篩(最好用40〜120目的篩網),以 做成藥草粉末。 經濟部智慧財產局員工消費合作社印製 (2) 麥門冬的根切細後放煎釜中,加水浸泡,水量最好 以滿過草藥至少10公分。加熱此浸水之麥門冬到97〜103 °C 的溫度約60分鐘,共煎煮兩次以製取麥門冬的萃取液。此 麥門冬的萃取液用篩網(約100目)過濾。收集濾液後, 濾液在溫度50〜60°C及壓力400〜650 mm-Hg下濃縮到所需濃 度。此濃縮液最好爲麥門冬濾液的1/14量。 (3) 麥門冬濃縮液與其他藥材的粉末混合,混合物送到 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -16- 1233804 A7 _- _ B7Dlwan et al. Published in g 8 3) '2 7: 3 2-36, revealing the effect of juice extracted from pneumonia leaves on wound closure and granulation growth, similar to dexamethasone, but in tension and In terms of epithelial formation, it has an antagonistic effect with dexamethasone. Gan et al. Disclosed in Chinese Medicine ^^ (197 7) ′ 8 · 5 26 ′ the leaves of pneumonia grass can be used for anti-inflammatory, antipyretic, treatment of pneumonia and cough. The preparation method of STA-36 and STA-4 herbal composition is as follows: A. Preparation of SJA-36 herbal composition The preparation method of STA-36 herbal composition is as follows: (1) Roots of Pinellia ternata, licorice and ginseng and pneumonia The whole grass is finely cut, dehydrated, honed and sieved with a sieve (preferably a sieve of 40 to 120 mesh) to make a herbal powder. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs (2) The roots of Mai Mendong are cut into small frying pots and soaked in water. The water volume should be at least 10 cm over the herbs. Heat this water-soaked asparagus to a temperature of 97 ~ 103 ° C for about 60 minutes, and cook for two times to prepare an extract of asparagus. The extract of this asparagus was filtered through a sieve (about 100 mesh). After the filtrate was collected, the filtrate was concentrated to a desired concentration at a temperature of 50 to 60 ° C and a pressure of 400 to 650 mm-Hg. The concentrated solution is preferably 1/14 the amount of the aspartate filtrate. (3) The mixture of Ophiopogon condensate and other medicinal materials is sent to the paper. The size of the paper is applicable to the Chinese National Standard (CNS) A4 (210X297 mm) -16- 1233804 A7 _- _ B7
五、發明説明(A 流動造粒機及用濾布做好的噴管中。造粒機設定在9 0〜11 〇 °C預熱5分鐘後,混合物即開始造粒,每次噴霧時間約 (請先閱讀背面之注意事項再填寫本頁) 4 0〜5 5秒,噴到一定量後,噴布管即拍振,以振落粉末,其 拍振頻率爲每1 〇秒一次。造粒後,顆粒經乾燥並冷卻, 然後過篩,再包裝於聚乙烯(P E )袋中。顆粒的水分含量 最好在6 %以下。顆粒可再充塡於任何種類的傳統膠囊中 ’包括天然明膠、果膠 '酪蛋白、膠原、蛋白、修改的澱 粉及聚乙烯吡咯烷酮(PVP )。 B. STA-4草藥組成物的製備 STA-4草藥組成物依下法製備 I、 肺炎草 (1 ) 肺炎草全草切細。 (2 ) —份(重量)的肺炎草飮片加20份(體積比)的 50%酒精(萃取溶媒)。 (3 )藥草及溶媒以迴流加熱萃取約3 0分鐘,如此產生 肺炎草的酒精浸膏。 經濟部智慧財產局員工消費合作社印製 (4)萃取液冷卻後,用篩網(約100目)過濾,將濾 液收集起來。濾液以減壓濃縮方法在溫度50〜60 °C (最好 5 5°C )及真空度約30托(torr )下取得濃縮物。濃縮物中 固形物的含量約爲生藥的7 · 8 %重量比。濃縮物中固形物的 含量爲濃縮物除去50%酒精者。以肺炎草爲例,其濃縮物 中固形物的含量與濃縮物量差不多(因濃縮物中水分甚少 之故)。 ____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -17- 1233804 A7 經濟部智慧財產局員工消費合作社印製 ______ B7五、發明説明( (5 )濃縮物中再加入適量的玉米澱粉(一種賦型劑) 以做成糊狀物。 (6 )糊狀物用噴霧乾燥法製成肺炎草顆粒(最好約爲 生藥的42%重量比)。 II、 半夏、甘草及花旗參 (1 )半夏塊莖及甘草與花旗參的根分別切細。 (2 )每種草藥的各一份(重量)加約20倍(容積比) 的水。 (3 )每種浸水中的生藥各予加熱煎煮約30分鐘使各別 產生半夏、甘草及花旗參的含水浸膏。 (4 )每種浸膏冷卻後,以篩網(約1 〇〇目)過濾。分 別收集濾液,每種濾液以減壓濃縮方法在溫度50〜60°C (最 好55°C )及真空度約30托(torr)下取得液態濃縮物。最 好是半夏濃縮物的固形物含量爲半夏生藥的20%,甘草濃 縮物的固形物含量爲甘草生藥的20%,花旗參濃縮物的固 形物含量爲花旗參生藥的24.3%。濃縮物中固形物的含量爲 濃縮物除去水分者。 (5 )每種濃縮物中再加入適量的玉米激粉(一種賦 型劑)並以噴霧乾燥法製成各別草藥的顆粒。 (6 )每種顆粒連同肺炎草顆粒混合成混合的顆粒。 III、 麥門冬 麥門冬塊莖依II、( 1 )〜(4 )的步驟製成濃縮物。麥 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -18- 1233804 A7 B7 五、發明説明(、 門冬濃縮物與其它半夏、甘草及花旗參濃縮物唯一不同的 是,麥門冬濃縮物含相當量的水分,而其它的濃縮物幾不 含水分。以9公克的麥門冬生藥來說,其濃縮物重約5.4公 克,其中固形物占2.25公克,水分占3.15公克。 麥門冬的液態濃縮物再與其它草藥顆粒混合之。 STA-36及STA-4中各生藥的公克重如表3a所示。 表3a ST A-36及ST A-4中各生藥的公克重 麥門冬 半夏 甘草 花旗參 肺炎草 總重 (口服劑量) STA-36 /STA-4 (劑量比) 原料 9g 6g 3g 3g 3g 24 g STA-36 5,40 g (2.25gSC* +3.15g 水分) 6g (生藥粉) 3 g (生藥粉) 3g (生藥粉) 3 g (生藥粉) 20.4 g (生藥粉) 2 STA-4 5.40g濃縮物 (2.25gSC* +3.15g 水分) 1.50g顆粒 (1.20gSC* + 0.30g玉米澱粉) 0.63g顆粒 (0.60gSC* + 0.03g玉米殿粉) 0.96g顆粒 (0.73gSC* + 0.¾玉米麵 1.25g顆粒 (0.25gSC* + 1.02g玉米澱粉) 10.20g (9.74g的顆粒 及麥門冬濃縮 物+0.46g玉米 殿粉) 1 * S C =固形物含量,即乾燥的濃縮物(濃縮物除去水分 或溶媒者) 表3a的原料列所示的是每種草藥處理前的重量。而 STA-36及STA-4列顯示的是(1)每種草藥的最終型態及其 (2 )最終重量。例如,STA-36中除麥門冬是濃縮物型態外 ,半夏、甘草、花旗參及肺炎草皆爲草藥粉末型態。又, 除麥門冬的重量較其原料輕之外,其餘草藥粉末皆保持與 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁) •^1 、-口 - 經濟部智慈財產局員工消費合作社印製 1233804 kl ___ _B7 五、發明説明(^ 原料同重。 (請先閱讀背面之注意事項再填寫本頁) 可是在STA-4中,除麥門冬維持與STA-36中者同爲濃 縮物最終型態外,其餘草藥在經過萃取,濃縮及製粒後, 其公克重皆著實地降低了,如表3a所示。此外,爲了幫助 濃縮物在造粒時的安定性’每種濃縮物皆加入一種賦型劑 (如玉米澱粉),其量則視濃縮物的安定性而定。STA_4的 最終產品是顆粒型態,其重量約爲STA-36的一半,雖兩者 是由同量的原料作成的。 下述例子係解說性的,切勿視爲限制本發明的範圍者 。在不逾越本發明的範圍內,得做合理的變動,如此技藝 人士所慣用者。 例1 闬高效液相層析法來對STA-36及STA-4中 的草藥做品質管制 經濟部智慧財產局員工消費合作社印製 本發明用高效液相層析法(HPLC )來確保草藥的品質 受到良好的管制。有三種HPLC方法被開發來配合每種草藥 的化學及生理特性。這三種方法分述如下。 (A)HPLC分析方法1 方法1使用前置管柱Lichrospher R P — 1 8 ( endcapped) ( 5 ’ 4 · 0 內徑X 1 〇mm ’ Merck)及V. Description of the invention (A in the mobile granulator and the nozzle made with filter cloth. The granulator is set to 90 ~ 110 ° C for 5 minutes, and the mixture starts to granulate. (Please read the precautions on the back before filling in this page.) 4 ~ 5 5 seconds, after spraying a certain amount, the spray tube will beat to shake the powder, and the beat frequency is once every 10 seconds. After granulation, the granules are dried and cooled, then sieved, and then packed in polyethylene (PE) bags. The moisture content of the granules is preferably below 6%. The granules can be refilled in any kind of traditional capsules' including natural Gelatin, pectin 'casein, collagen, protein, modified starch and polyvinylpyrrolidone (PVP). B. Preparation of STA-4 herbal composition. Preparation of STA-4 herbal composition. I. Pneumonia (1) The whole pneumonia grass is shredded. (2) — 20 parts (by volume) of 50% alcohol (extraction solvent) of pneumonia grass tablets. (3) Extraction of herbs and solvents under reflux for about 30 minutes This produces an alcohol extract of pneumonia. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs (4) After the extract is cooled, filter through a sieve (about 100 mesh) and collect the filtrate. The filtrate is concentrated under reduced pressure at a temperature of 50 to 60 ° C (preferably 55 ° C) and a vacuum of about 30 Torr. (Torr) to obtain a concentrate. The solid content in the concentrate is about 7.8% by weight of the crude drug. The solid content in the concentrate is that the concentrate removes 50% alcohol. Take pneumonia as an example, its concentration The content of solids in the material is similar to that of the concentrate (due to the low water content in the concentrate). ____ This paper size applies to China National Standard (CNS) A4 (210X 297 mm) -17- 1233804 A7 Intellectual Property of the Ministry of Economic Affairs Printed by the Bureau's Consumer Cooperatives B___ V. Description of the invention ((5) Add appropriate amount of corn starch (an excipient) to the concentrate to make a paste. (6) The paste is made by spray drying Into pneumonia grass granules (preferably about 42% by weight of crude drugs) II. Pinellia ternata, licorice root and American ginseng (1) pinellia tubers and roots of licorice and American ginseng are shredded separately. (2) each herb Each portion (weight) is added with about 20 times (volume ratio) water. (3) Each dip The crude drugs in the water are preheated and boiled for about 30 minutes each to produce aqueous extracts of Pinellia ternata, licorice and American ginseng. (4) After each extract is cooled, it is filtered through a sieve (about 1000 mesh). The filtrate was collected, and each filtrate was concentrated under reduced pressure to obtain a liquid concentrate at a temperature of 50 to 60 ° C (preferably 55 ° C) and a vacuum of about 30 torr. The solid substance of the pinellia concentrate is preferred. The content is 20% of Pinellia crude drug, the solid content of licorice concentrate is 20% of licorice crude drug, and the solid content of ginseng concentrate is 24.3% of ginseng crude drug. The content of the solids in the concentrate is one in which the concentrate removes moisture. (5) An appropriate amount of corn powder (an excipient) is added to each concentrate, and granules of the respective herbs are prepared by spray drying. (6) Each granule is mixed with pneumonia granules to form mixed granules. III. Asparagus tuber The asparagus tuber is made into a concentrate according to steps II, (1) to (4). Mai (please read the notes on the back before filling this page) This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) -18- 1233804 A7 B7 V. Description of the invention (, Asparagus concentrate and other half The only difference between summer, licorice, and American ginseng concentrates is that the asparagus concentrate contains a considerable amount of water, while the other concentrates contain almost no moisture. For 9 grams of asparagus crude, the concentrate weighs about 5.4 grams, of which solids account for 2.25 grams, and moisture accounts for 3.15 grams. The liquid concentrate of oatmeal is mixed with other herbal granules. The gram weight of each crude drug in STA-36 and STA-4 is shown in Table 3a. 3a ST A-36 and ST A-4 The total weight of each crude drug of O. asparagus, Pinellia oleifera, Ginseng, Pseudomonas pneumoniae (oral dose) STA-36 / STA-4 (dose ratio) Raw materials 9g 6g 3g 3g 3g 24 g STA-36 5,40 g (2.25gSC * + 3.15g moisture) 6g (drug powder) 3 g (drug powder) 3g (drug powder) 3 g (drug powder) 20.4 g (drug powder) 2 STA-4 5.40 g concentrate (2.25gSC * + 3.15g moisture) 1.50g granules (1.20gSC * + 0.30g corn starch) 0.63g granules (0.60gSC * + 0.03g corn flour) 0.96g granules (0.73gSC * + 0.23 corn flour 1.25g granules (0.25gSC * + 1.02g corn starch) 10.20g (9.74g granules and wheat asparagus concentrate + 0.46g corn palace Powder) 1 * SC = solid content, that is, dry concentrate (concentrate removes water or solvent) The raw material column in Table 3a shows the weight of each herb before treatment. STA-36 and STA-4 columns Shown are (1) the final form of each herb and (2) the final weight. For example, in STA-36, except for asparagus in a concentrated form, Pinellia ternata, licorice, American ginseng, and pneumonia are all herbs Powder type. In addition, except for the weight of oatmeal as compared with its raw materials, the remaining herbal powders are in accordance with the Chinese National Standard (CNS) A4 specification (210X 297 mm) for this paper size. (Please read the note on the back first Please fill in this page for the matters) • ^ 1,-口-Printed by the Consumer Cooperatives of the Intellectual Property Office of the Ministry of Economic Affairs, printed 12338804 kl ___ _B7 V. Description of the invention (^ The raw materials have the same weight. (Please read the notes on the back before filling this page ) However, in STA-4, except for asparagus, it is the same as STA-36. , The remaining herbs after extraction, was concentrated and granulation, which are gram weight really reduced, as shown in Table 3a. In addition, in order to help the stability of the concentrates when granulating, each excipient is added with an excipient (such as corn starch), and the amount depends on the stability of the concentrate. The final product of STA_4 is a pellet type, and its weight is about half that of STA-36, although both are made from the same amount of raw materials. The following examples are illustrative and should not be construed as limiting the scope of the invention. Reasonable changes may be made within the scope of the present invention, as used by those skilled in the art. Example 1 闬 Quality control of herbal medicines in STA-36 and STA-4 by high performance liquid chromatography. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. The invention uses high performance liquid chromatography (HPLC) to ensure the herbal medicines. Quality is well regulated. Three HPLC methods were developed to match the chemical and physiological characteristics of each herb. These three methods are described below. (A) HPLC analysis method 1 Method 1 uses a pre-column Lichrospher R P — 1 8 (endcapped) (5 ′ 4 · 0 inner diameter X 1 〇mm ’Merck) and
Cosmosil 5C18— MS 管(5//m Nacalai tesque -20- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1233804 A7 B7 五、發明説明()8 5 C18— MS ,內徑4 · 6x25〇 mm)在室溫操 (請先閱讀背面之注意事項再填寫本頁) 。管柱的移動相採梯度沖提,含(A ) Η 2 0 : K Η 2 P〇4 :10%H3P〇4 (1000mi : 2 . 7 2 g : 1 m 1 ;v / w / v ) ; ( B ) C H 3 C N ; (C)H2〇&(D )C H 3 ◦ H。梯度沖提程式如表4所示,流速爲i .〇 m 1 /m i n,檢測波長2 5 0 n m,分析時間爲6 0分 表4 方法1巧動相吃磨度沖提程式 一時間(分) (A)(%) (B)(%) (C)(%) (D)(%) — 開始 90 10 0 0 30 75 25 0 0 — 40 65 35 0 0 _ 55 0 75 25 0 ^ 60 0 10 90 0 後續沖提1 5 m i η 經濟部智慧財產局員工消費合作社印製 (B)HPLC分析方法2 Η P L· C分析方法2 ’使用前置管柱Lichrospher R P - 18 ( endcapped ) ( 5 //m,4 · 0 內徑x 1 Omrr ,Merck )及 Cosmosil 5C 1 8— MS 的管柱(5//rr Nacalai tesque 5 C 1 8— MS ,4 . 6 內徑x 2 5 〇 mm),工作溫度3 5 °C其移動相採梯度沖提,含(a ) 10mM KH2P〇4+l OmM K 2 Η P 0 4 + 本紙張尺度適用中國國家標準(CNS ) A4規格(210χ 297公釐) -21 - 1233804 A7 B7 五、發明説明(^ 0 . 01%H3p〇4(KH2P〇4:K2HP〇4: 10 /^H3P〇4*H2〇二 1 · 36g : 1 · 74g : 1ml :1 0 0 0 ml) ; ( b ) C Η 3 C N ; ((:)^12〇及( D ) C Η 3〇Η,其梯度沖提程式如表5所示。流出速爲 1 . 0 m 1 / m i 1Ί檢測波長2 6 0 n m,分析的總滯留 時間爲3 5分。 表5 , 去2移動相的梯度沖提程式 時間(分) s (A) (B) (C) (D) 開始 100 0 0 0 25 60 0 20 20 30 20 0 20 60 35 100 0 0 0 後續沖提1 5 m i n (C ) Η P L C分析方法3 方法3用 Lichrospher RP - 1 8爲前置管柱及 Cosmosil 5 C 1 8 — M S 的管柱(5 // m,Nacalai tesque ,5C18— MS,4.6 內徑x25〇mm),工作溫 度3 5 °C,移動相爲梯度沖提,含(A ) Η 2〇: KH2PO4 (1000ml : 2 . 72g ^ v/w);( B ) C H 3 C N ; (C) H2〇及(D) CH3〇H,其梯 度沖提程式如表6所示。流出速度爲1 . 0 m 1 / m i n 檢測波長2 0 3 n m,分析時間爲6 0分。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)Cosmosil 5C18— MS tube (5 // m Nacalai tesque -20- This paper size applies to Chinese National Standard (CNS) A4 specifications (210X297 mm) 1233804 A7 B7 V. Description of the invention) 8 5 C18— MS, inner diameter 4 · 6x25mm) operate at room temperature (please read the precautions on the back before filling this page). Mobile phase mining gradient extraction of the column, including (A) Η 20: K Η 2 P0 4: 10% H3P 0 4 (1000mi: 2.72 g: 1 m 1; v / w / v); (B) CH 3 CN; (C) H2O & (D) CH 3 ◦ H. The gradient extraction program is shown in Table 4. The flow rate is 1.0 m 1 / min, the detection wavelength is 250 nm, and the analysis time is 60 minutes. Table 4 Method 1 ) (A) (%) (B) (%) (C) (%) (D) (%) — start 90 10 0 0 30 75 25 0 0 — 40 65 35 0 0 _ 55 0 75 25 0 ^ 60 0 10 90 0 Subsequent extraction 1 5 mi η Printed by (B) HPLC Analytical Method 2 of the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 2 Η PL · C Analytical Method 2 'Using the pre-column Lichrospher RP-18 (endcapped) (5 // m, 4 · 0 inner diameter x 1 Omrr, Merck) and Cosmosil 5C 1 8-MS column (5 // rr Nacalai tesque 5 C 1 8- MS, 4.6 inner diameter x 2 5 0 mm) , Working temperature 3 5 ° C, its mobile phase mining gradient extraction, containing (a) 10mM KH2P〇4 + l OmM K 2 Η P 0 4 + This paper size applies Chinese National Standard (CNS) A4 specifications (210χ 297 mm ) -21-1233804 A7 B7 V. Description of the invention (^ 0.01% H3p〇4 (KH2P〇4: K2HP〇4: 10 / ^ H3P〇4 * H20) 22 · 36g: 1 · 74g: 1ml: 1 0 0 0 ml); (b) C Η 3 CN; ((:) ^ 12〇 and (D) C Η 3〇Η, the gradient extraction The formula is shown in Table 5. The outflow rate is 1.0 m 1 / mi 1Ί, the detection wavelength is 260 nm, and the total retention time of the analysis is 35 minutes. Table 5. Gradient extraction program time (min. ) S (A) (B) (C) (D) Start 100 0 0 0 25 60 0 20 20 30 20 0 20 60 35 100 0 0 0 Subsequent extraction 1 5 min (C) Η PLC analysis method 3 method 3 Use Lichrospher RP-1 8 as the pre-column and Cosmosil 5 C 1 8 — MS (5 // m, Nacalai tesque, 5C18- MS, 4.6 inner diameter x 25mm), working temperature 3 5 ° C, The mobile phase is a gradient elution, containing (A) Η 20: KH2PO4 (1000 ml: 2.72 g ^ v / w); (B) CH 3 CN; (C) H 2 0 and (D) CH 3 0 H, the gradient The extraction procedure is shown in Table 6. The outflow velocity was 1.0 m 1 / m i n, the detection wavelength was 2 0 3 n m, and the analysis time was 60 minutes. This paper size applies to China National Standard (CNS) A4 (210X297 mm) (Please read the precautions on the back before filling this page)
、1T 經濟部智慧財產局員工消費合作社印製 -22- 1233804 A7 B7 五、發明説明(i 表6 方法3移動相的梯度沖提程式 時間(分) (Α) (Β) (C) (D) 開始 80 20 0 〇 40 65 35 0 0 55 0 80 20 0 60 0 20 80 0 後續沖提1 5 m i η (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 STA-36中所用草藥的HPLC分析方法包括方法,主要 指標成分及每味草藥的檢測波長,皆綜列於表7中。STA-36的草藥的HPLC圖譜載示於圖1〜圖5。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) l2338〇4 _ 五、發明説明(4 7 表Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs, 22T-1233804 A7 B7 V. Description of the invention (i Table 6 Method 3 Gradient extraction program time for mobile phase (minutes) (Α) (Β) (C) (D ) Start 80 20 0 〇40 65 35 0 0 55 0 80 20 0 60 0 20 80 0 Subsequent withdrawal 1 5 mi η (Please read the precautions on the back before filling out this page) The HPLC analysis methods for the herbs used in the production of STA-36 include methods, the main index components and the detection wavelength of each herb are summarized in Table 7. The HPLC chart of the herbs of STA-36 is shown in Figures 1 to 5. This paper size applies to China National Standard (CNS) A4 specification (210X297 mm) l2338〇4 _ V. Description of invention (4 7 table
析 分 C L Ρ Η 的 藥 草 用 所 6 3 - A T S 草藥名 Η P L C分析 指標成分 滯留時間 檢測波長 —-- 方法 (分) (nm) 麥門冬 方法1 6115-1 11.5 214 ----—_ 6115-2 13.0 214 半夏 方法2 腺嘌呤 14.8 250 --- 鳥糞嘌呤 17.0 250 _甘草 方法1 甘草酸 46.4 250 花旗參 方法3 人參皂苷 37.5 203 Rbi 肺炎草 方法1 FY-1 28.0 250 FY-2 31.6 250 FY-3 33.5 250 (請先閲讀背面之注意事項再填寫本頁) •«丨 、1Τ 經濟部智慧財產局S工消費合作杜印製 在HPLC分析前,先將〇·5公克的草藥檢體與 2 0 m 1的7 0 %甲醇溶液混合。在室溫下檢體溶液以超 音波振擾1 5分鐘’放在4 0 °C的迴轉水洛中2 0分I里’ 迴轉速率爲每分1 6 0轉。檢液放置3 0分,使渣粒沉澱 。以吸管吸取1 0 m 1上淸液,並通過0 . 4 5 // m的濾 膜。濾液就可用來作Η P L C分析。取濾液2 0 // 1做 Η P L C分析。 結果 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -24- 1233804 A7 B7 五、發明説明(; 麥門冬的Η P L C層析圖譜如圖1所示。如表7所載 ’用Η P L C分析法1 ’以2 1 4 n m波長檢測。在麥門 冬的Η P L C圖譜上可辨認出二個明顯的波峰,6 1 1 5 一 1及6 1 1 5 — 2。6 1 1 5 — 1的滯留時間爲 1 1 · 5分,6 1 1 5 - 2者爲1 3分,雖然此二波峰的 化學成分未鑑定出來,它們可用來確保麥門冬的品質。 半夏的HP L· C層析圖譜如圖2所π。如表7所載, 用Η P L C分析法2,以25〇]1111波長檢測,半夏有二 個顯著指標成分,腺嘌呤及鳥糞嘌呤(adenine及gUanosine ),二者皆爲核酸成分。腺嘌呤(adenine )有升高醛縮酶 (a 1 d ο 1 a s e )的效果。腺嘌呤的滯留時間爲 1 4 . 8分,鳥糞嘌呤者爲1 7分。 甘草的Η P L C層析圖示於圖3。如表7所示,用 Η P L C分析法1 ,以2 5 0 n m波長檢測甘草,在甘草 的Η P L C層析圖中發現1個化學指標成分,甘草酸( Glycyrrhizin )。甘草酸(C42H62〇16)是一個很甜的 物質’已知它具有解毒,消炎及溶血作用,並被用於治療 愛迪生症。其滯留時間爲4 6 . 4分。 花旗參的Η P L C層析圖示於圖4。如表7所示,使 用Η P L C分析法3,在2 0 3 n m波長下檢測花旗參。 在其HP L C層析圖中發現一化學指標成分,人參皂苷 R b i。人參皂苷r b i對擴張血管,消除疲勞及避免溶血 等有藥效。 肺炎草的HPLC層析圖示於圖5。如表7所示,用 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇X 297公羡) (請先閱讀背面之注意事項再填寫本頁) ^1 經濟部智慧財產局員工消費合作社印製 - 25- [233804 A7 ____________B7Analysis of CL P Η for Herbal Medicine 6 3-ATS Name of Herbal Medicine PLC Analysis Index Component Retention Time Detection Wavelength-Method (Minutes) (nm) Maimendong Method 1 6115-1 11.5 214 -------- 6115-2 13.0 214 Pinellia method 2 Adenine 14.8 250 --- Guanosine 17.0 250 _Glycyrrhiza method 1 Glycyrrhizic acid 46.4 250 American ginseng method 3 Ginsenoside 37.5 203 Rbi Pneumonia method 1 FY-1 28.0 250 FY-2 31.6 250 FY-3 33.5 250 (Please read the notes on the back before filling out this page) Specimens were mixed with a 70% methanol solution of 20 m 1. The specimen solution was ultrasonically perturbed for 15 minutes at room temperature 'and placed in a rotary water cylinder at 40 ° C for 20 minutes and 1 li. The rotation rate was 160 revolutions per minute. Leave the test solution for 30 minutes to settle the slag particles. Aspirate 10 m 1 of scum solution with a straw and pass through a filter membrane of 0.4 5 // m. The filtrate was then used for ΗPLC analysis. Take the filtrate 2 0 // 1 for Η P L C analysis. Result This paper size is in accordance with Chinese National Standard (CNS) A4 specification (210X 297 mm) -24-1233804 A7 B7 V. Description of the invention (; The chromatogram of the PLC of Tomomi maidenensis is shown in Figure 1. As shown in Table 7 It is detected using the Η PLC analysis method 1 ′ at a wavelength of 2 1 4 nm. Two distinct peaks can be identified on the Η PLC spectrum of Mai Mendong, 6 1 1 5 1 and 6 1 1 5 — 2. 6 The retention time of 1 1 5 — 1 is 1 1 · 5 minutes, and 6 1 1 5-2 is 1 3 minutes. Although the chemical composition of the two peaks has not been identified, they can be used to ensure the quality of Ophiopogon. The HP L · C chromatogram of Figure 2 is shown in Figure 2. As shown in Table 7, using the PLC analysis method 2 and detected at a wavelength of 251111, pinellia has two significant index components, adenine and guanine. (Adenine and gUanosine), both of which are nucleic acid components. Adenine has the effect of increasing aldolase (a 1 d ο 1 ase). The retention time of adenine is 14.8 points, and guanopurine The score is 17 points. The PLC chromatogram of Glycyrrhiza uralensis is shown in Figure 3. As shown in Table 7, Glycyrrhiza uralensis was analyzed with G. PLC analysis method 1 at a wavelength of 250 nm. A chemical index component of Glycyrrhiza chinensis was found in the PLC chromatogram. Glycyrrhizin. Glycyrrhizin (C42H62〇16) is a very sweet substance. 'It is known to have detoxification, anti-inflammatory and hemolytic effects and is used in Treatment of Edison. Its retention time is 46.4 minutes. The Η PLC chromatogram of ginseng is shown in Figure 4. As shown in Table 7, Η PLC analysis method 3 was used to detect ginseng at a wavelength of 230 nm. A chemical index component was found in its HP LC chromatogram, ginsenoside R bi. Ginsenoside rbi is effective in dilating blood vessels, eliminating fatigue and avoiding hemolysis. The HPLC chromatogram of pneumonia is shown in Figure 5. As shown in Table 7, the Chinese standard (CNS) A4 specifications (21 × X 297) are applicable to this paper size (please read the precautions on the back before filling out this page) ^ 1 Printed by the Employees ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs System-25- [233804 A7 ____________B7
五、發明説明(A Η P L C分析法1 ,在2 5 0 n m波長下檢測肺炎草。發 現有四個顯著波峰F Y - 1〜F Y - 4。F Y —;[的滯留 時間爲2 8 . 〇分、F γ 一 2爲3 1 · 6分、F γ — 3爲 3 3 · 5为 F Y - 4爲1 8 . 3分。由於此四波峰外觀 始終一致,故儘管其化學成分仍未鑑定出來,它們依然可 以用來鑑別肺炎草,並確保其品質。 例 薄層遷法(T L C )來鑑別甘苜、麥門冬、 半夏及肺炎苣 (請先閱讀背面之注意事項再填寫本頁) •馨丨 除ΗV. Description of the invention (A Η PLC analysis method 1, pneumonia detected at a wavelength of 250 nm. Four significant peaks FY-1 ~ FY-4 were found. FY —; [retention time of 28.8. , F γ-2 is 3 1 · 6 points, F γ-3 is 3 3 · 5 is FY-4 is 18.3 points. Since the appearance of the four peaks is always the same, although its chemical composition has not been identified, They can still be used to identify pneumonia and to ensure its quality. For example, Thin Layer Migration (TLC) method to identify Glycyrrhiza, Oleifera, Pinellia and Pneumonia (please read the precautions on the back before filling this page) • Xin
S T A 經濟部智慧財產局Μ工消費合作社印製 T L 做爲固定 來決定用 乙醇,依 溶媒對甘 水及乙醇 。此第二 媒含氯仿 二溶媒對 5 // 1 點 含移動相 P L C外,薄層層析法(TL C )也可用來鑑定 3 6醫藥組成物c C使用矽膠6 0 相,及三種移動 何種溶媒。第一 4 : 1 : 2 ( v 草的鑑定特別好 ,依 5 : 2 : 1 溶媒對鑑定麥門 及甲醇,依5 : 鑑別肺炎草特別 在T L C板上。 溶媒,讓溶媒上 一些草藥。 F 2 5 4 ( 相(或展開 種溶媒含乙 / v / v ) 用。第二種 (V / V / 冬及花旗參 1 ( v / v 好用。做T T L C放在 移9公分。 附著於T )溶媒, 酸乙酯, 的容積比 溶媒含丁 v )的容 特別好用 )容積比 L C測定 T L C槽 T L C測 L C板上) 視草藥特性 4 N氨水及 例。第一種 醇,4 N氨 積比例混合 。第二種溶 混合。此第 時,將檢體 室內,槽內 定結果分述ST A Printed by the Intellectual Property Bureau of the Ministry of Economic Affairs of the Ministry of Economic Affairs and Consumer Cooperatives as the fixed to determine the use of ethanol, according to the solvent on the water and ethanol. This second medium contains two chloroform solvents, 5 // 1 point contains mobile phase PLC, thin layer chromatography (TL C) can also be used to identify 3 6 pharmaceutical composition c C using silicone 60 phase, and three types of mobile Kind of solvent. The first 4: 1: 2 (v) grass identification is particularly good, according to the 5: 2: 1 solvent pair identification of wheat gate and methanol, according to 5: identification of pneumonia grass is particularly on the TLC board. Solvent, let some herbs on the solvent. F 2 5 4 (phase (or expanded solvent containing B / v / v) is used. The second type (V / V / winter and American ginseng 1 (v / v is easy to use. Place it as a TTLC and move it by 9 cm. Attach to T The volume ratio of the solvent, ethyl acetate, and the solvent containing butyl v) is particularly good.) The volume ratio LC measurement TLC tank TLC measurement LC plate) Depending on the characteristics of the herbal medicine 4 N ammonia and examples. The first alcohol is mixed with 4 N ammonia. The second solution is mixed. At this time, the results of the test room and the tank are described in detail.
、1T 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) -26- 1233804 A7 B7 五、發明説明(1 如下: (A )甘草 T L C分析甘草使用固定相爲附著於τ L C板 膠6 0 F 2 5 4,移動相爲乙酸乙酯:4 N氨水: 4 : 1 : 2 (v/v/v)。檢體點在TLC板後, 丁 L C板放入含移動相槽室內,溶媒的高度勿超過 板上施點檢體的水平線位置。讓溶媒後升到離原點 時,取出T L C板,並讓其在空氣中乾燥。乾燥後, T L C板噴以香莢蘭醛/硫酸的試劑,並在1 〇 5 2分鐘,板上會在R f約=〇 · 5的位置出現一黃 代表甘草。R f二呈色點到施點檢體之點的距離/ 動距離(即9 c m )。 上的矽 把 T L C 9 c XXX °c加熱 色點, 溶媒移 (請先閱讀背面之注意事項、再填寫本頁} ^1 -訂 經濟部智慧財產局員工消費合作社印製 (B )麥門冬 T L C分析麥門冬使用固定相爲附著於τ L C板上的 矽膠6 0 F 2 5 4,移動相爲正丁醇:4 N氨水:乙醇= 5 : 2 : 1 ( v / v / v )。施點檢體後,T L C板放入 含移動相溶媒的T L C槽室內,其溶媒的高度勿超過 T L C板上施點檢體之原點位置。讓溶媒移升離原點達 9 c m時,取出T L C板,令其在空氣中乾燥後,將香莢 蘭醛/硫酸的試劑噴在T L C上,並以1 〇 5 °C加熱2分 鐘。有一代表麥門冬的褐色點出現在R f = 〇 . 4位置。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -27- 1233804 A7 B7 五、發明説明(土 (C )花旗參 分析花旗參的T L C,所使用固定相爲附著於T L C 板上的矽膠6 0 F 2 5 4,移動相爲正丁醇:4 N氨水: 乙醇=5 : 2 : 1 ( v / v / v )。經施點檢體,T L C 板放入含移動相溶媒的T L C槽室內,溶媒的高度勿超過 T L C板上施點檢體原點位置。讓溶媒移升離原點達9 cm 距離時,取出T L C板,讓其在空氣中乾燥後,T L C板 噴以香莢蘭醛/硫酸的試劑,並以1 0 5 t度加熱2分鐘 。TL C板上在R f = 〇 . 3位置出現一代表花旗參的紫 色點。 (D)肺炎草 分析肺炎草的T L C所使用固定相爲附著於T L C板 上的ί夕膠60F254,移動相爲氯仿:甲醇=5 : 1 ( ν / ν )。施點檢體後,T L C板放入含移動相溶媒的 TL C槽室內,溶媒的高度勿超過TL C板上施點檢體原 點位置。讓溶媒移升到離原點9 c m時,取出T L C板, 讓其在空氣中乾燥,將T L C板放在紫外線檢測器,以 3 6 6 n m波長檢測,在R f二0 . 3位置可見一代表肺 炎草的淡黃點。 例3 測定動物體內IgG,IgE,IL-4及IFN-v的方法 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) «1 、11 經濟部智慧財產局員工消費合作社印製 -28- 1233804 A7 經濟部智慧財產局員工消費合作社印製 ___B7______五、發明説明(▲ STA - 3 6和STA - 4及所含各個草藥,被用來 硏究其對B A L B / C小鼠經以塵蟎抗原(D e r P 5 ) 敏感化後誘生的免疫球蛋白G ( I g G )、免疫球蛋白E (I g E )及細胞介白素4 ( I L 一 4 )等的效用。塵蟎 是家中灰塵中的小蟲,它如同抗原會對有特異反應的人, 造成過敏性氣喘的反應。 實驗之設計 (A )動物 雌性B A L B / C小鼠,4〜6周大,重約2 0公克 ,取自國立台灣大學動物飼養中心。動物的性別及年齢要 符合每一實驗。 (B )塵蟎過敏原D e r P 5之純化 使用p G E X - 2 T質體來表現大腸桿菌(E. coli )中 的塵蟎抗原5 -谷胱甘肽S -轉移酶(G S T )。融合蛋 白的分子量約爲4 2 k D。此蛋白是用谷胱甘肽結合的瓊 脂糖膠管柱層析法來純化。利用受轉殖(transfected )的大 腸桿菌,培養在含胺苄青黴素(Ampicillin) ( 1 0 〇 // g / m 1 )的培養液中,來選取一個對塵蟎D e r P 5 -G S T呈陽性反應的單一菌落(c ο 1 ο n y )。再培養此菌落使 產生足量之塵蟎抗原(Der P5 - GST)。然後收 集細菌培養液並用離心分離。去掉上淸液’菌體用T B S (p Η 7 . 5 )洗滌後收集於離心管中。在T B S沖開後 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) -29- 1233804 A7 B7 五、發明説明( 隨即將0 . 1 Μ 苯甲基磺醯氟(Phenylmethylsulfonyl fluoride)加入菌液中,再加 D N a s e I ,T w e e η 2 0,及溶菌素(Lysozyme)。菌液利用冷凍解凍程序來 釋出塵蟎抗原(D e r P 5 — G S T )蛋白。之後將 E D T A加入細胞裂解液中,並以離心方式分離,離心後 丟棄沉澱物,上淸液倒入含谷胱甘肽結合的瓊脂糖膠吸附 管柱中,此管柱可吸附塵蟎抗原De r P5 - GST。 管柱先用T B S緩衝液在4 °C下淸洗,再用含還原態的谷 胱甘肽的T r i s — b a s e ( p Η 8 · 0 )淸洗,以將 塵蟎抗原D e r P 5 - G S T從瓊脂糖膠粒中分離出來 。塵蟎抗原De r P5 - GST的純度可用SDS - P A G E確認之。蛋白的量可用傳統的蛋白分析法量測之 〇 (C )動物之致敏化 B A L B / c小鼠先予腹腔注射1 〇 // g的塵蟎抗原 (D e r P 5 )及4 m g的氫氧化鋁(衛氏藥廠, Punchbowl,Australia )使之致敏化。第一次致敏後7天, 除安慰劑組外,其他各組小鼠飼以中草藥組成物STA-36和 STA-4直到第2 1天結束。 第一次致敏後第2 1天,小鼠再追加一次塵蟎抗原 D e r P 5。在第2次追加注射後第4 8小時,將小鼠 放置於圓形塑膠容器中,再用〇 · 1% D e r P5以 超音波噴霧式刺激之(Challenge)。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閲讀背面之注意事項再填寫本頁) «丨、 1T This paper size applies the Chinese National Standard (CNS) A4 specification (210X 297 mm) -26- 1233804 A7 B7 V. Description of the invention (1 as follows: (A) Licorice TLC analysis Licorice uses a stationary phase attached to a τ LC plate Gel 6 0 F 2 5 4, mobile phase is ethyl acetate: 4 N ammonia: 4: 1: 2 (v / v / v). After the sample point is on the TLC plate, the DLC plate is placed in the chamber containing the mobile phase. , The height of the solvent should not exceed the horizontal position of the sample on the plate. When the solvent rises to the original point, remove the TLC plate and let it dry in the air. After drying, spray the TLC plate with vanillin / Sulfuric acid reagent, and in 105 minutes 2 minutes, a yellow licorice will appear on the plate at a position where R f = about 0.5. The distance between the two colored points of R f and the point where the specimen is applied / moving distance ( That is 9 cm). The silicon on the TLC 9 c XXX ° c heats the color point, and the solvent is moved (please read the precautions on the back, and then fill out this page) ^ 1-Order printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs ( B) TLC analysis of asparagus. Asparagus uses a stationary phase of silicone 6 0 F 2 5 4 attached to a τ LC plate, and a mobile phase of n-butanol: 4 N ammonia water: ethanol = 5: 2: 1 (v / v / v). After applying the sample, place the TLC plate in the TLC tank containing the mobile phase solvent, and do not exceed the height of the solvent on the TLC plate. The origin of the body. When the solvent is moved up to 9 cm from the origin, remove the TLC plate and allow it to dry in the air. Spray the vanillin / sulfuric acid reagent on the TLC, and set it at 105 ° C is heated for 2 minutes. A brown spot representing Macedonian appears at the position of R f = 0.4. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -27- 1233804 A7 B7 V. Description of the invention (Earth (C) American Ginseng TLC analysis of American Ginseng. The stationary phase used was silicone 6 0 F 2 5 4 attached to the TLC board, and the mobile phase was n-butanol: 4 N ammonia: ethanol = 5: 2: 1 (v / v / v). After applying the sample, the TLC plate is placed in the TLC tank containing the mobile phase solvent, and the height of the solvent should not exceed the origin of the sample on the TLC plate. Let the solvent move away from the origin. At a distance of 9 cm, take out the TLC plate and allow it to dry in the air. Spray the TLC plate with vanillin / sulfuric acid reagent, and apply Heat for 2 minutes. A purple spot representing American ginseng appears at R f = 0.3 on the TLC plate. (D) Pneumonia spp. The stationary phase used for the TLC analysis of pneumonia spp. Is a latex glue 60F254 attached to the TLC plate. The mobile phase is chloroform: methanol = 5: 1 (ν / ν). After applying the specimen, the T L C plate is placed in the TL C tank containing the mobile phase solvent. The height of the solvent should not exceed the position of the origin of the specimen on the TLC plate. When the solvent is moved up to 9 cm from the origin, remove the TLC plate and allow it to dry in the air. Place the TLC plate in an ultraviolet detector and detect it at a wavelength of 3 6 6 nm. One can be seen at the position R f 0.2. Represents a yellowish spot of pneumonia. Example 3 Method for determination of IgG, IgE, IL-4 and IFN-v in animals This paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) (Please read the precautions on the back before filling this page) «1 11. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs -28- 1233804 A7 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs ___B7______ V. Description of the invention (▲ STA-3 6 and STA-4 and the various herbs contained in it, It was used to investigate the immunoglobulin G (I g G), immunoglobulin E (I g E) and cells induced by BALB / C mice sensitized with dust mite antigen (Der P 5). Effectiveness of interleukin 4 (IL-4), etc. Dust mites are small worms in the dust in the house. It acts like an antigen and can cause allergic asthma in people with specific reactions. Experimental design (A) Animal female BALB / C mice, 4 to 6 weeks old, weighing about 20 grams, taken from the National Taiwan University Animal Feeding Center. The sex and age of the animals must meet each experiment. (B) Purification of the dust mite allergen Der P 5 Using p GEX-2 T plastids to express dust mite resistance in E. coli 5-Glutathione S-transferase (GST). The molecular weight of the fusion protein is about 4 2 k D. This protein is purified by glutathione-conjugated agarose gel column chromatography. E. coli (transfected) was cultured in a culture solution containing Ampicillin (100 / g / m1) to select a single colony (positive response to the dust mite Der P 5 -GST ( c ο 1 ο ny). The colony was cultured again to produce a sufficient amount of dust mite antigen (Der P5-GST). Then the bacterial culture solution was collected and separated by centrifugation. The supernatant liquid was used to remove TBS (p Η 7. 5) ) Collected in a centrifuge tube after washing. After TBS is opened (please read the precautions on the back before filling this page) This paper size is applicable to China National Standard (CNS) A4 size (210 × 297 mm) -29- 1233804 A7 B7 V. Description of the invention (Immediately 0.1 M phenylmethylsulfonyl fluoride (Phenylmethylsulfonyl fluoride) is added to the bacterial solution, and then DN ase I, T wee η 2 0, and lysozyme (Lysozyme) are added. The bacterial solution is thawed by freezing. Procedures to release dust mite antigen (Der P 5 — GST) protein EDTA was added to the cell lysate and separated by centrifugation. The pellet was discarded after centrifugation, and the supernatant was poured into a column containing glutathione-bound agarose gel. This column can absorb dust mite antigens. De r P5-GST. The column was first washed with TBS buffer at 4 ° C, and then washed with Tris — base (p Η 8 · 0) containing reduced glutathione to remove the dust mite antigen Der P 5- GST was isolated from the agarose gel particles. The purity of the dust mite antigen De r P5-GST can be confirmed by SDS-P A G E. The amount of protein can be measured by traditional protein analysis methods. Sensitized BALB / c mice that were sensitized to animals were injected intraperitoneally with 10 // g dust mite antigen (Der P 5) and 4 mg of hydrogen. Alumina (Weich's Pharmaceutical, Punchbowl, Australia) sensitized it. Seven days after the first sensitization, the mice in each group except the placebo group were fed with the Chinese herbal medicine composition STA-36 and STA-4 until the end of the 21st day. On the 21st day after the first sensitization, the mice were supplemented with dust mite antigen De r P 5 again. At 48 hours after the second additional injection, the mice were placed in a round plastic container, and then stimulated with 0.1% De r P5 by ultrasonic spraying (Challenge). This paper size applies to China National Standard (CNS) A4 (210X 297 mm) (Please read the precautions on the back before filling this page) «丨
、1T 經濟部智慧財產局員工消費合作社印製 - 30- 1233804 A7 B7 五、發明説明(4 刺激後數小時即利用苯巴比妥(phenobarbital) 100 mg/ml麻醉老鼠,並從心臟或尾靜脈採血,此血在室溫下靜 置1小時,然後離心分離,血淸收集存於- 8 0 °C備供 E L I S A分析IgE、IgG2a (見下述)。肺泡沖洗液則以 lOOOrpm離心10分鐘,其上淸液用來分析細胞素(cytokine) 、IL-4及IFN-γ。細胞沉澱物則以PBS沖開,利用細胞離心 (c y t ◦ s p i η)計算發炎細胞。 (D) D e r P 5 —特異性I g G及I g E的測定. 測定D e r P 5 -特異性I g G及I g E的量是使 用”酵素聯結免疫定量分析法” (E L I S A )。在對蛋 白質有強吸附力的微滴盤上面,塗被以1 0 0 // 1濃度爲 10 m g / m 1的純化D e r P 5,利用塗被緩衝液(含 3%BSA ;pH 二 7·4 之 PBS)稀釋成 5//g/ml。此微 滴盤在4 t:溫度下靜置一夜後,經含0.05% Tween 20之 PBS沖洗三次後,以3 % ( w / v重量/容積)的B S A 一 P B S緩衝液於2 5 °C環境下塡塞2小時。 測定I g G時稀釋至1 : 1 0 0,測定I g E時稀釋 至1 : 1 0並做二次重覆。在4 °C S?置一夜,加入結合生 物素(Biotin)之大鼠抗-小鼠的I g E之單株抗體,或大鼠 抗-小鼠之I g G之單株抗體,這些抗體是稀釋於 〇_ 0 5 %的明膠緩衝液(Gelatin buffer)中,加入抗體後2 小時,淸洗6次,再加入抗生物素蛋白(Avidin) -鹼性磷酸 酶(1 : 1 0 0 0 )溶液,並再在2 5 °C下放置1小時。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ·«1 訂 經濟部智慧財產局員工消費合作社印製 1233804 A7 B7 五、發明説明(‘ 呈色反應可於加入磷酸酶基質磷酸對硝苯酯二鈉鹽(pNPP ’鹼性磷酸酶基質,Sigma N-2770)並利用免疫微滴盤判讀 機(ELISA讀取機,DyneX MRX )以波長4 0 5 n m判讀。 讀値可對照市售同型的標準品,也就是小鼠抗- T N P抗 體單株抗體,IgGl (1〇7.3) ,IgG2a ( G 1 5 5 - 1 7 8 ),及 IgE(IgE- 3)。 (E)細胞素(IL-4及IFN-γ)的ELISA測定 高蛋白高結合力的微滴盤(Costar,No· 3590 )塗被以 純化的抗細胞素抗體(測定IL-4時用2pg/ml的 PharMinge 18191D IL-4 抗體;測定 IFN-γ 時用 3pig/ml 的 PharMinge 18181D IFN-γ抗體)。微滴盤用含3%BSA的PBS溶液加以 塗被,再用含0.05% Tween-20, pH7.4的PBS溶液淸洗。 將100 μΐ的肺泡液的上澄液,連同細胞素標準液,加 於微滴盤,放置在4°C下,反應一個晚上。然後把100 μΐ 的生物素-小鼠-IL-4(PharMinge 1 8042D,1 pg/ml)或生物 素-抗小鼠-IFN-γ ( PharMinge 18112D,1 pg/ml )加入微滴 盤。反應2小時後,加入100 μΐ的抗生物素蛋白-鹼性磷酸 鹽(1:1000 ) ( Streptavidin-AP, PharMinge 1 3043E )至微 滴盤中同時振搖1小時。200 μΐ的磷酸酶基質磷酸對硝苯 酯二鈉鹽(pNPP,鹼性磷酸酶基質,Sigma Ν-2770)加入微 滴盤使之起呈色反應。微滴盤用微滴盤判讀機(ELISA讀 取機,Dynex MRX)在波長40 5 nm下讀取之。 本纸張尺度適用中國國家標準(CNS ) A4規格(2!0'乂297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 -32- A7 1233804 ___ B7_ _____ 五、發明説明()〇 (F )測定肺功能 (請先閱讀背面之注意事項再填寫本頁) 靜脈注射1 00 mg/ml的苯巴比妥(Phenobarbital)於小鼠 後,將一根PE50的管子插入氣管內。管子連到一具呼吸測 量儀上測定呼氣及吸氣。另一根PE50的管子則插入食道, 以測定食道壓來代替通肺壓(TTP )。當壓力信號傳到生理 記錄器BR8000時,信號被放大並轉成呼吸容量及通肺壓以 計算氣管壓。實驗中小鼠尾靜脈一直插著滯留針,用於注 射乙醯膽鹼以改變氣管壓力變化。 4、統計 實驗所有數據皆以「平均値±SEM」來計算。氣管經乙 醯膽鹼引起的阻力改變,轉成PC 1 00後,所測値以平均値 iS EM表示之。IgE及IgG2a依吸光値測定。各組間的有意 義差用史氏試驗(Student’s t-test)決定。以p<0.05表示統 計學上有意義差。 例4 草藥含水浸膏對IgG及IgE的效用 經濟部智慧財產局員工消費合作社印製 種種水萃取法已對花旗參及肺炎草試過,以決定那一 種形式的含水浸膏最合適草藥組成物。 花旗參以(1 )粉末,(2 ) 9 5 %酒精浸膏,(3 )水浸 膏及(4) 50%酒精浸膏等形式來試驗其抑制IgE及IgG2a 的藥效。如圖6所示,花旗參的50%酒精浸膏對抑制IgE效 果最佳,雖然其對減少IgG2a的效果沒有95%酒精浸膏來的 好。然而由於抗原媒介的免疫失調症是一種主要由IgE媒 本紙張尺度適用中國國家標準(CNS ) A4規格{ 210X297公釐) - 33- A7 1233804 __ B7Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs of the Ministry of Economic Affairs of the People's Republic of China-30- 1233804 A7 B7 V. Description of the invention (4 A few hours after stimulation, anesthetize mice with phenobarbital 100 mg / ml, and remove them from the heart or tail vein Blood was collected, and the blood was allowed to stand at room temperature for 1 hour, and then centrifuged. The blood pupae were collected and stored at -80 ° C for ELISA analysis of IgE and IgG2a (see below). The alveolar lavage solution was centrifuged at 1,000 rpm for 10 minutes. The supernatant was used to analyze cytokine, IL-4 and IFN-γ. The cell pellet was washed away with PBS, and the inflammatory cells were calculated by cell centrifugation (cyt ◦ spi η). (D) D er P 5 —Determination of specific I g G and I g E. To determine the amount of Der P 5 -specific I g G and I g E, use "enzyme-linked immunoassay" (ELISA). There is strong adsorption on proteins The top of the forceful microtiter plate was coated with purified Der P 5 at a concentration of 10 0 // 1 at 10 mg / m 1, and diluted with coating buffer (containing 3% BSA; PBS pH 2 · 4). 5 // g / ml. After the microtiter disk was left standing at 4 t: overnight, it was washed three times with 0.05% Tween 20 in PBS. 3% (w / v weight / volume) BSA-PBS buffer was choked for 2 hours at 25 ° C. Diluted to 1: 1 0 when measuring I g G, and diluted to 1: 1 when measuring I g E: 10 and repeat it twice. Incubate at 4 ° C overnight, add the monoclonal antibody of rat anti-mouse I g E that binds to Biotin, or rat anti-mouse I g Monoclonal antibodies to G. These antibodies are diluted in 0.05% gelatin buffer, 2 hours after antibody addition, rinsed 6 times, and then added avidin-alkaline phosphate Enzyme (1: 1 0 0 0) solution, and then left at 25 ° C for 1 hour. This paper size applies the Chinese National Standard (CNS) A4 size (210X 297 mm) (Please read the precautions on the back before (Fill in this page) · «1 Order printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1233804 A7 B7 V. Description of the invention ('The color reaction can be added to the phosphatase base phosphate p-nitrophenyl ester disodium salt (pNPP' alkaline phosphate Enzyme substrate, Sigma N-2770) and read with an immune microplate reader (ELISA reader, DyneX MRX) at a wavelength of 40 5 nm. Read 値Isotype control standard commercially available, i.e. mouse anti - T N P antibody monoclonal antibody, IgGl (1〇7.3), IgG2a (G 1 5 5 - 1 7 8), and IgE (IgE- 3). (E) ELISA for measuring cytokines (IL-4 and IFN-γ). Microtiter disks (Costar, No. 3590) with high protein and high binding capacity are coated with purified anti-cytokine antibodies (2pg for IL-4 measurement) / ml of PharMinge 18191D IL-4 antibody; 3pig / ml of PharMinge 18181D IFN-γ antibody was used to measure IFN-γ). The microtiter disks were coated with a PBS solution containing 3% BSA, and then rinsed with a PBS solution containing 0.05% Tween-20, pH 7.4. The supernatant of 100 μΐ of alveolar fluid, together with the cytokine standard solution, was added to a microtiter plate, and placed at 4 ° C for one night. Then 100 μΐ of biotin-mouse-IL-4 (PharMinge 1 8042D, 1 pg / ml) or biotin-anti-mouse-IFN-γ (PharMinge 18112D, 1 pg / ml) was added to the microtiter disk. After 2 hours of reaction, 100 μΐ of avidin-basic phosphate (1: 1000) (Streptavidin-AP, PharMinge 1 3043E) was added to the microtiter plate while shaking for 1 hour. 200 μΐ of phosphatase substrate p-n-phenylphenyl phosphate disodium salt (pNPP, alkaline phosphatase substrate, Sigma N-2770) was added to the microtiter plate to cause a color reaction. The microtiter disk was read with a microtiter disk reader (ELISA reader, Dynex MRX) at a wavelength of 40 5 nm. This paper size applies the Chinese National Standard (CNS) A4 specification (2! 0 '乂 297 mm) (Please read the precautions on the back before filling this page) Ordered by the Intellectual Property Bureau of the Ministry of Economic Affairs and printed by the Consumer Cooperatives -32- A7 1233804 ___ B7_ _____ 5. Description of the invention () 〇 (F) Measurement of lung function (please read the precautions on the back before filling this page) Intravenous injection of phenobarbital (100 mg / ml) in mice Insert a PE50 tube into the trachea. The tube was connected to a breathing meter to measure exhalation and inspiration. Another PE50 tube was inserted into the esophagus to measure the esophageal pressure instead of the pulmonary pressure (TTP). When the pressure signal is transmitted to the physiological recorder BR8000, the signal is amplified and converted into breathing volume and pulmonary pressure to calculate tracheal pressure. In the experiment, a retention needle was inserted into the tail vein of the mouse to inject acetylcholine to change the change in tracheal pressure. 4. Statistics All the data in the experiment are calculated by "mean 値 ± SEM". The change in resistance of trachea caused by acetylcholine was converted to PC 100, and the measured 値 was expressed as mean 値 iS EM. IgE and IgG2a were determined by absorption spectrometry. The significance difference between the groups was determined using the Student's t-test. Statistical significance was expressed as p < 0.05. Example 4: The effect of herbal extracts on IgG and IgE. Various water extraction methods printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs have been tested on American ginseng and pneumoniae to determine which form of aqueous extract is the most suitable herbal composition. . American ginseng was tested in the form of (1) powder, (2) 95% alcohol extract, (3) water extract, and (4) 50% alcohol extract to test its effectiveness in inhibiting IgE and IgG2a. As shown in Figure 6, the 50% alcohol extract of American Ginseng has the best effect on inhibiting IgE, although its effect on reducing IgG2a is not as good as that of 95% alcohol extract. However, because the antigen-mediated immune disorder is a type mainly composed of IgE media, the paper size applies the Chinese National Standard (CNS) A4 specification {210X297 mm)-33- A7 1233804 __ B7
五、發明説明(A (請先閲讀背面之注意事項再填寫本頁) 介的疾病,花旗參的50%酒精浸膏在草藥組成物中,看來 能提供組成物最佳的IgE減低的效果。但若將由花旗參浸 膏作成的顆粒加到其它草藥的顆粒時,則花旗參的水浸膏 作成的顆粒卻對IgE的抑制及IgG的上昇,提供較好效果 。因此STA-4組成物中的花旗參爲水萃取的。 肺炎草以(1 )粉末,(2 ) 9 5 %酒精浸膏,(3 )水浸 膏及(4) 50%酒精浸膏等形式來試驗其抑制IgE,IgG2a, IL - 4及IF N - γ的藥效。如圖7所示,肺炎草的5 0 %酒精浸骨 產生最好的IgE及IgG2a抑制效果,雖然肺炎草的水浸膏顯 示對IL-4及IFN-γ的的抑制效果最好。但由於硏究時發現肺 炎草的水浸膏引起動物的血塊,故不考慮用於人類。 例5 比較 STA-36 及 STA-4 對 IgE,IgG2a,IL-4,IFN-γ 及肺功會旨的效用 經濟部智慧財產局員工消費合作社印製 上例3動物實驗中有做硏究以比較草藥組成物STA-36 及STA-4對IgE,IgG2a,IL-4,IFN-γ及肺功能的效用。硏 究結果如圖8 - 1 0所示。 圖8顯示草藥組成物STA-36及STA-4對小鼠IgG及 IgE的效用的比較硏究。如圖8所不,兩個草樂組成物 STA-36及STA-4與控制組比較,顯示對IgE有抑制,此作 用STA-4比STA-36大的多。與控制組比較,STA-4顯示統 計上的顯著差異。但STA-36及STA-4皆對IgG無抑制作用 。事實上,在STA-36及STA-4兩組中,IgG値反而增高。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) - 34- A7 1233804 ______B7______ 五、發明説明(4 圖9顯示STA-36及STA-4對小鼠肺功能的影響。STA-36及STA-4兩組皆比控制組對肺功能有意義的改善( ρ<0·05)。此兩組間STA-4對肺功能的改善較STA-36佳, 雖然STA_4與STA-36之間的數値並無有意義差,可能是每 組的動物數(η )不充足所致。 圖 10 比較 STA-4 與傳統氣喘藥如 ketotifen, prednisolone 及 aminophylline 對 IgE,IgG,IL-4 及 IFN-γ的 效用。結果顯示,只有STA-4展示對IgE有意義的減少及 對IgG, IL-4及IFN-γ有意義的增多,說明 STA-4比 ketotifen,prednisolone 及 aminophylline 對氣喘具有較佳療 效。 圖10也說明STA-4的療效與一般的先抑壓IL-4,再間 接地減少IgE値的作用機制不同。本例的情行是,於服用 STA-4後,IL-4及IFN-γ雙雙大量地增加,故IgE的減少不 是由於IL-4的減少所致。相反的,IFN-γ的量(由TH1細胞 所產生)在STA-4的治療後,顯著增加。IFN-γ刺激β細胞 以合成並分泌IgG2a,這說明了何以在STA-4的治療中, IgG2a的量增加。故推測STA-4的效果部份是由IgG2a所致 。此IgG2a在第二次接觸過敏原時,會與過敏原做用,以 降低過敏反應。 例6 ^藥組成物STA-36及STA-4的毒性試驗 草藥組成物的毒性試驗是根據28天口服亞毒性硏究所 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 -35- !233804 A7 ^-———;-------B7 五、發明説明(^-— 測袼之死亡率,眼科檢查,臨床症候及大體解剖的結果 其結果如表8〜10所示。 |S^服用—STA-3^^jTA-4後小鼠之死亡率 ~——— ------ X Li. _2 % T w e e η 8 0 水溶液 STA-36 STA-4 ^[量(mg/kg/天) 5000 ------- _5000 — 性別 — 雄 雄 —雄 一 小鼠數 10 10 10 — 死亡率 0/10 0/10 0/10 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 ^9小鼠服用STA-36及STA-4後的眼科檢查及臨床症候 2%Tween 80水溶液 STA-36 STA-4 劑量(mg/kg/天) 5000 5000 _ 性別 雄 雄 雄 小鼠數 10 10 10 開始前 (第0天) 0/10 0/10 0/10 大體解剖前 (第28天) 0/10 0/10 0/10 臨床症候 0/10 0/10 0/10 -36- 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨〇><297公釐) 1233804 A7 B7 五、發明説明(& 象10 服用STA-36及3丁八-4_^|勺大體解剖 2 % T w e e η 8 0水溶液 STA-36 STA-4 劑量(mg/kg/天) 5000 5000 性別 雄 雄 雄 小鼠數 10 10 10 異常器官 0/10 0/10 0/10 表8〜10的結果顯示本硏究中STA-35及STA-4皆未顯 示亞毒性的症候。 詳述本發明並參照較佳具體例後,對熟悉此技藝人士 而言,在不偏離後列附錄申請專利範圍所界定範圍,做修 改及變化,顯然是可行的。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -37 - 本紙張尺度適用中國國家標準(CNS ) A4規格(公釐)V. Description of the invention (A (please read the precautions on the back before filling out this page), the 50% alcohol extract of American ginseng in the herbal composition appears to provide the best IgE reduction effect of the composition However, if the granules made from American Ginseng extract are added to the granules of other herbs, the granules made from American Ginseng's water extract will inhibit IgE and increase IgG and provide better results. Therefore, the composition of STA-4 The American ginseng is extracted from water. Pneumoniae is tested for its IgE inhibition in the form of (1) powder, (2) 95% alcohol extract, (3) water extract and (4) 50% alcohol extract. The pharmacological effects of IgG2a, IL-4 and IF N-γ. As shown in Fig. 7, a 50% alcohol extraction of pneumonia in bone produced the best IgE and IgG2a inhibitory effect, although the water extract of pneumonia showed an effect on IL- 4 and IFN-γ have the best inhibitory effect. However, it was found that the water extract of pneumoniae caused blood clots in animals during investigation, so it was not considered for use in humans. Example 5 Comparison of STA-36 and STA-4 for IgE and IgG2a , IL-4, IFN-γ and Pulmonary Function Purpose Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs Experiments were conducted to compare the effects of herbal ingredients STA-36 and STA-4 on IgE, IgG2a, IL-4, IFN-γ, and lung function. The results of the study are shown in Figure 8-10. Figure 8 The comparison of the effects of the herbal compositions STA-36 and STA-4 on mouse IgG and IgE is shown. As shown in Figure 8, the comparison of the two herb compounds STA-36 and STA-4 with the control group shows that IgE is inhibited, and this effect is much greater in STA-4 than in STA-36. Compared with the control group, STA-4 shows a statistically significant difference. However, both STA-36 and STA-4 have no inhibitory effect on IgG. In fact, In the two groups of STA-36 and STA-4, IgG was increased. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm)-34- A7 1233804 ______B7______ 5. Description of the invention (4 Figure 9 shows STA Effects of -36 and STA-4 on lung function in mice. Both STA-36 and STA-4 groups have significant improvement in lung function compared with the control group (ρ < 0.05). Between these two groups, STA-4 on lung function The improvement of the function is better than that of STA-36. Although there is no significant difference in the number between STA_4 and STA-36, it may be caused by the insufficient number of animals (η) in each group. Figure 10 Comparing STA-4 and traditional Effect of asthma drugs such as ketotifen, prednisolone and aminophylline on IgE, IgG, IL-4 and IFN-γ. The results showed that only STA-4 showed a significant reduction in IgE and a significant increase in IgG, IL-4 and IFN-γ It shows that STA-4 has better effect on asthma than ketotifen, prednisolone and aminophylline. Figure 10 also shows that the efficacy of STA-4 is different from the general mechanism of first suppressing IL-4 and then indirectly reducing IgE 値. The behavior of this case is that after taking STA-4, both IL-4 and IFN-γ increase significantly, so the decrease in IgE is not due to the decrease in IL-4. In contrast, the amount of IFN-γ (produced by TH1 cells) increased significantly after treatment with STA-4. IFN-γ stimulates β cells to synthesize and secrete IgG2a, which explains why the amount of IgG2a is increased in the treatment of STA-4. Therefore, it is speculated that the effect of STA-4 is partly caused by IgG2a. This IgG2a will interact with the allergen when it is exposed for the second time to reduce the allergic reaction. Example 6 ^ Toxicity test of the pharmaceutical composition STA-36 and STA-4 The toxicity test of the herbal composition is based on the 28-day oral subtoxicity laboratory. The paper size applies the Chinese National Standard (CNS) A4 specification (210 × 297 mm) ( Please read the precautions on the back before filling this page) Order printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs -35-! 233804 A7 ^ -------; ------- B7 V. Description of Invention (^- — Mortality test, eye examination, clinical symptoms and gross anatomy results are shown in Tables 8 to 10. | S ^ Math mortality after taking STA-3 ^^ jTA-4 ~ ———— ------ X Li. _2% T wee η 8 0 Aqueous solution STA-36 STA-4 ^ [Amount (mg / kg / day) 5000 ------- _5000 — Gender-Male-Male-Young Number of rats 10 10 10 — Mortality 0/10 0/10 0/10 (Please read the notes on the back before filling out this page) Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs ^ 9 Mice take STA-36 and STA Ophthalmological examination and clinical symptoms after -4 2% Tween 80 aqueous solution STA-36 STA-4 dosage (mg / kg / day) 5000 5000 _ sex number of male and female mice 10 10 10 (Day 0) 0/10 0/10 0/10 Before gross anatomy (Day 28) 0/10 0/10 0/10 Clinical symptoms 0/10 0/10 0/10 -36- This paper size applies to China National Standard (CNS) A4 specification (2 丨 〇 < 297 mm) 1233804 A7 B7 V. Description of the invention (& Elephant 10 taking STA-36 and 3 Ding Ba-4_ ^ | Spoon gross anatomy 2% T wee η 8 0 Aqueous solution STA-36 STA-4 Dose (mg / kg / day) 5000 5000 Sex Number of male and female mice 10 10 10 Abnormal organs 0/10 0/10 0/10 Tables 8 to 10 show the results. In the study, neither STA-35 nor STA-4 showed symptoms of subtoxicity. After describing the invention in detail and referring to the preferred specific examples, for those skilled in the art, without departing from the scope defined in the appendix of the appended patent application, Modifications and changes are obviously feasible. (Please read the notes on the back before filling out this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs -37-This paper size applies to China National Standard (CNS) A4 specifications (mm )
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/949,610 US6503542B2 (en) | 2000-12-14 | 2001-09-12 | Herbal compositions for treating immunological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI233804B true TWI233804B (en) | 2005-06-11 |
Family
ID=36592596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW91120752A TWI233804B (en) | 2001-09-12 | 2002-09-11 | Herbal pharmaceutical compositions for treating immunological disorders |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI233804B (en) |
-
2002
- 2002-09-11 TW TW91120752A patent/TWI233804B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Research progress on main symptoms of novel coronavirus pneumonia improved by traditional Chinese medicine | |
| EP3566702B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy, comprising baicalein as active ingredient | |
| CN101002841B (en) | Effective parts of rose and preparation method thereof | |
| AU2002241544B9 (en) | Herbal pharmaceutical compositions for treating immunological disorders | |
| TWI284040B (en) | Herbal compositions for treating immunological disorders | |
| AU2002241544A1 (en) | Herbal pharmaceutical compositions for treating immunological disorders | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN101569712B (en) | A kind of traditional Chinese medicine composition for treating cold and wind-cold | |
| Savrikar et al. | Bhaishajya Kalpanaa-the Ayurvedic pharmaceutics-an overview | |
| CN113499381B (en) | Application of traditional Chinese medicine composition and/or pharmaceutical preparation containing traditional Chinese medicine composition in resisting influenza virus | |
| CN102861255A (en) | Preparation method and quality control method for medicine and preparation thereof for treating influenza | |
| CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
| TWI233804B (en) | Herbal pharmaceutical compositions for treating immunological disorders | |
| CN114099609B (en) | Pharmaceutical composition for treating cough and preparation method thereof | |
| CN107095979B (en) | Traditional Chinese medicine composition suitable for treating hyperlipidemia, preparation method and application thereof | |
| CN101670088B (en) | Traditional Chinese medicine composite for treating acute/chronic bronchitis | |
| CN100375626C (en) | Chinese medicine compound preparation for treating depression and its preparation method | |
| CN108743893A (en) | The preparation method and applications of clearing lung-heat soup side's Chinese medical extract | |
| WO2017101210A1 (en) | Gastritis treating traditional chinese medicine composition preparation method and preparation | |
| JP7671874B2 (en) | Use of herbal medicine composition in the manufacture of a medicament for treating cough asthma | |
| CN102657699B (en) | Cane sugar-containing and sugar-free Shenkun blood nourishing granules with longer period of validity | |
| KR102356654B1 (en) | An anti-inflammatory and analgesic formula comprising propolis and goji berry | |
| CN109432193B (en) | A kind of medicinal composition for treating cough and preparation method thereof | |
| CN108403995B (en) | Wind-dispelling and dampness-removing extraction composition, preparation method and application thereof | |
| CN104873662B (en) | A kind of Chinese materia medica preparation and preparation method thereof for treating acute and chronic pharyngitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |